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SUMMARY 
 
Patients with chronic gastro-oesophageal reflux disease are predisposed to Barrett’s 
metaplasia and oesophageal adenocarcinoma.  The availability of molecular markers 
that can objectively identify patients with Barrett’s oesophagus at increased risk of 
carcinoma is highly desirable.  A literature search was conducted to identify 
potentially useful biomarkers for genotype-phenotype correlation studies in South 
African patients with Barrett’s oesophagus.   
 
The COX-2, c-myb and c-myc genes selected for mRNA expression analysis were 
analysed in 26 patients with Barrett’s metaplasia (BM) without dysplasia; 14 with 
Barrett’s oesophagus and dysplasia (BD); 2 patients with Barrett’s adenocarcinoma 
(BAC); 19 with erosive oesophagitis (ERD); 25 with non-erosive oesophagitis 
(NERD) and 19 control individuals with a normal gastroscopy and no gastro-
oesophageal reflux disease (GORD) symptoms.  In the BD/BAC group, 69% (11/16) 
showed increased c-myb mRNA expression compared with 35% (9/26) in the BM 
group (p = 0.03).  A statistically significant difference (p = 0.002) in c-myb expression 
was also observed between Barrett’s patients (20/42, 48%) and the control groups 
(9/63, 14%).  In the BD patients, 21% (3/14) had increased c-myc mRNA expression 
compared with none in those with BM (p < 0.05) and BAC.  No significant differences 
in mRNA expression levels were observed between ethnic groups for the genes 
analysed. 
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In an attempt to determine whether the low expression level of c-myc in the study 
cohort may be related to possible gene-gene interaction, DNA samples of 199 
individuals were subjected to genotyping of the functional GT-repeat polymorphism 
in the promoter region of the NRAMP1/SLC11A1 gene.  Both these genes are 
involved in iron metabolism and c-myc is known to repress NRAMP1/SLC11A1.  
Genotype and allele frequencies were similar in all the groups studied with the 3/3 
genotype being the most common.  However, none of the three above-mentioned 
BD patients with increased c-myc mRNA expression had the 3/3 genotype.  
Therefore, although small in number, c-myc-NRAMP1/SLC11A1 interaction may be 
of adverse significance in patients with allele 2.   
 
TP53 mutation analysis was performed on 68 Barrett’s patients, and TP53 
immuno-staining on oesophageal biopsy specimens of 55 subjects.  Sporadic 
TP53 mutations were not identified in any of the patients with BM or dysplasia 
without BAC.  Immuno-histochemistry staining of 2+ and 3+ intensity was similar 
in patients with metaplasia and dysplasia (58%).  The low mutation frequency and 
relative non-specificity of TP53 immunostaining observed in Barrett’s patients 
seem to preclude its widespread use as a screening tool.  TP53 mutation 
detection may however be useful for risk stratification once dysplasia has been 
diagnosed, as mutations G245R and D281Y were identified in two patients with 
BAC.   
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Of the genes studied in the South African population, c-myb represents the most 
useful marker for early detection of an increased cancer risk in Barrett’s patients.  In 
future, patients with Barrett’s oesophagus may benefit from genetic assessment to 
complement existing cancer surveillance and treatment strategies. 
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OPSOMMING 
 
Pasiënte met kroniese gastro-esofageale refluks se risiko vir Barrett se metaplasie 
(BM) en esofageale adenokarsinoom is verhoog.  Daar is ’n behoefte vir molekulêre 
merkers wat objektiewe identifikasie van hoё-risiko pasiёnte met Barrett esofagus 
moontlik sal maak.  ’n Literatuurstudie is uitgevoer om potensieel bruikbare merkers 
te identifiseer vir genotipe-fenotipe studies in Suid-Afrikaanse pasiënte met Barrett 
esofagus. 
 
Die COX-2, c-myb en c-myc gene wat geselekteer is vir mRNA uitdrukking analise is 
geanaliseer in 26 pasiënte met Barrett metaplasie (BM) sonder displasie;  14 met 
displasie (BD);  2 pasiënte met Barrett-geassosieerde adenokarsinoom (BAK);  19 
met erosiewe esofagitis;  25 met nie-erosiewe esofagitis en 19 kontrole pasiënte met 
‘n normale gastroskopie en sonder gastro-esofageale refluks simptome.  In die 
BD/BAK groep het 69% (11/16) verhoogde c-myb mRNS uitdrukking getoon, 
vergeleke met 35% (9/26) in die BM groep (p = 0.03).  ’n Statisties betekenisvolle 
verskil (p = 0.002) in c-myb mRNS uitdrukkking is ook waargeneem tussen Barrett 
pasiёnte (20/42, 48%) en die kontrole groepe (9/63, 14%).  In die pasiënte met BD, 
het 21% (3/14) verhoogde c-myc mRNS uitdrukking getoon vergeleke met geen in 
die BM (p < 0.5) en BAK groepe nie.  Geen betekenisvolle verskille in geen mRNS 
uitdrukking is waargeneem tussen die verskillende etniese groepe nie.   
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In ‘n poging om vas te stel of die lae vlak van c-myc uitdrukking wat waargeneem is 
verwant kan wees aan moontlike geen-geen interaksie, is die funksionele GT-
herhaling polimorfisme in die promoter streek van die NRAMP1/SLC11A1 geen 
geanaliseer in DNS monsters van 199 individue.  Beide gene is betrokke by yster 
metabolisme en c-myc opponeer die aksie van NRAMP1/SLC11A1.  Die 
NRAMP1/SLC11A1 genotipe en alleel frekwensies was soortgelyk in alle groepe wat 
bestudeer is, met die 3/3 genotipe die algemeenste.  Nie een van die pasiënte met 
BD en verhoogde c-myc mRNS-uitdrukking het ‘n 3/3 genotipe gehad nie.  Hoewel 
die getalle klein is, wil dit voorkom asof geen-geen interaksie tussen c-myc en 
NRAMP1/SLC11A1 moontlik kan bydra tot verhoogde risiko in pasiënte met alleel 2.   
 
TP53 mutasieanalise is uitgevoer op 68 Barrett pasiёnte en TP53 immuno-
histochemie kleuring op die esofageale weefsel van 55 pasiёnte.  Sporadiese TP53 
mutasies is nie in enige van die pasiёnte met BM of displasie sonder BAK 
waargeneem nie.  Immuno-histochemie kleuring van 2+ en 3+ intensiteit was 
dieselfde in pasiёnte met metaplasie en displasie (58%).  Die lae mutasie frekwensie 
en relatiewe nie-spesifisiteit van TP53 immunokleuring wat waargeneem is in Barrett 
se pasiёnte beperk wye gebruik van hierdie merker as sifting hulpmiddel.  
Identifikasie van TP53 mutasies kan egter bruikbaar wees vir risiko stratifisering 
nadat displasie gediagnoseer is, want mutasies G245R en D281Y is waargeneem in 
twee pasiёnte met BAK.   
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Van die gene wat bestudeer is in die Suid-Afrikaanse populasie, verteenwoordig c-
myb die mees bruikbare merker vir vroeё waarneming van verhoogde kanker risiko 
in Barrett pasiёnte.  In die toekoms kan pasiёnte met Barrett esofagus baat vind by 
genetiese bepalings wat bestaande opvolg vir kankerontwikkeling en behandeling 
strategieё komplimenteer. 
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LIST OF ABBREVIATIONS 
 
OAC   Oesophageal adenocarcinoma 
ACTB   Beta-actin 
Bam H1  restriction endonuclease enzyme 
BD   Barrett’s dysplasia 
BM   Barrett’s metaplasia 
BMI   Body mass index 
BO   Barrett’s oesophagus 
BSA   Bovine serum albumin 
cDNA   complementary DNA 
Χ2   Chi-Square 
CCK2   cholecystokinin 2 
CK    cytokeratin 
COX-2  Cyclo-oxygenase 2 
CLO   Columnar-lined oesophagus 
CLOtest®  rapid urease test 
DNA   deoxyribonucleic acid 
dATP   2΄-deoxyadenosine-5΄-triphosphate 
dCTP   2΄-deoxycytidine-5΄-triphosphate 
dGTP   2΄-deoxyguanosine-5΄-triphosphate 
dNTP   2΄-deoxyribonucleoside-5΄-triphosphate  
dTTP   2΄-deoxythymidine-5΄-triphosphate 
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DNAase  modifying enzyme, deoxyribonuclease 
ERD   Erosive reflux disease 
g/dL   gram per decilitre 
GORD  Gastro-oesophageal reflux disease 
GOJ   Gastro-oesophageal junction 
H&E   Hematoxylin and eosin 
HGD   High grade dysplasia 
IGD   Intermediate grade dysplasia 
LDA   Linear discriminant analysis 
LGD   Low grade dysplasia 
LOD   logarithm of odds 
LOH   Loss of heterozygosity 
LOS   Lower oesophageal sphincter 
M   molar, moles per litre 
Mg   magnesium 
MgCl2   magnesium chloride 
µg/L   microgram per litre 
µL   microlitre 
µmol/L  micro mole per litre 
µM   micro molar 
miz-1   c-myc-interacting zinc finger protein 1 
mM   milli molar 
NE   normal oesophagus   
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NERD             Non-erosive reflux disease 
ng   nanogram 
NO   nitric oxide 
NO2   nitrite 
NO3   nitrate 
NRAMP1  natural resistance-associated macrophage protein 1 
NSAID  Non-steroidal anti-inflammatory drug 
PAS   periodic acid Schiff 
PCR   polymerase chain reaction  
PG   prostaglandin 
pmol   picomol 
PNCA   proliferating cell nuclear antigen 
PPI   Proton pump inhibitor  
Rb   retinoblastoma 
RNA   ribonucleic acid 
RNAse  modifying enzyme, ribonuclease 
Rsa 1   restriction endonuclease enzyme 
RT-PCR  reverse transcriptase PCR 
SLC11A1  solute carrier family 11 member 1 
U   units 
yrs   age in years 
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CHAPTER 1 
 
INTRODUCTION 
 18
In the realm of gastro-oesophageal reflux disease (GORD), the most serious 
consequence is Barrett's metaplasia with the associated risk of oesophageal 
adenocarcinoma (OAC) (Cameron et al. 1995).  Barrett's oesophagus is diagnosed 
in approximately 6–12% of patients undergoing endoscopy for symptoms of GORD 
(Sarr et al. 1985; Cameron and Lomboy 1992).  It still remains unclear why some 
patients with GORD develop Barrett's oesophagus whereas others do not.  The 
symptoms of Barrett's oesophagus may be no different than those of conventional 
GORD uncomplicated by columnar metaplasia (Bonelli 1993).  Furthermore, there is 
a correlation between the length of Barrett's mucosa and the duration of 
oesophageal acid exposure (Loughney et al. 1998; Fass et al. 2001).  The 
mechanism whereby injury triggers metaplasia, and why this occurs in some but not 
all individuals, is unknown. 
 
Barrett's oesophagus is the condition in which columnar epithelium replaces the 
squamous epithelium that normally lines the distal oesophagus.  Of the three 
histological types of columnar epithelia described in Barrett’s oesophagus, 
specialised intestinal metaplasia is the most common.  This is also the only type that 
has a clear malignant potential and therefore the term “specialised intestinal 
metaplasia” should preferably be used when referring to the increased cancer risk in 
Barrett’s oesophagus (Spechler 1996).  Dysplasia in Barrett's mucosa is still the 
reference standard for assessing its pre-malignant potential, but histological 
classification is, unfortunately, subject to inter-observer error and interpretation 
problems (Alderson 2002; Levine 1997).   
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Oesophageal adenocarcinoma develops in approximately 0.5 percent of patients with 
Barrett's oesophagus per year (Shaheen et al. 2000).  This is a tumor found 
predominantly in white men, among whom the frequency of oesophageal 
adenocarcinoma has inexplicably quadrupled over the past few decades (Devesa et 
al. 1998).  Although GORD is the main recognised risk factor for this cancer 
(Lagergren et al. 1999), presumably because it causes Barrett's oesophagus, it is not 
clear whether the rising incidence of the tumor is due to an increasing frequency of 
GORD in the general population.   
Oxidative damage has long been related to carcinogenesis in human cancers and 
animal cancer models.  Various animal models (mainly rats) have been developed 
over recent years to study the possible involvement of iron in the pathogenesis of 
OAC.  The majority of these reports are consistent in their observation that iron 
supplementation promotes epithelial cell proliferation and inflammation (Goldstein et 
al. 1998; Chen et al. 1999a).  This enhances the production of reactive oxygen and 
nitrogen species in the oesophageal epithelium, which could lead to the formation of 
Barrett's oesophagus.  Wetscher et al. (1997) found that reactive oxygen species 
(ROS), as measured by chemiluminescence and lipid peroxidation, increased with 
the grade of oesophagitis and were the highest in columnar-lined oesophagus 
(CLO).  In a follow-up study by Chen et al. (2000), they suggested that according to 
their model, humans with gastro-oesophageal reflux and iron over-nutrition may be 
subject to the development of an oesophageal adenocarcinoma due to oxidative 
damage.  Oxidative damage has been proposed to be closely related to reflux 
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oesophagitis, a possible cause for CLO and a driving force for adenocarcinogenesis 
(Reid et al. 2001).   
  
The histological changes leading to adenocarcinoma are accompanied by alterations 
at the molecular level, including the accumulation of gene mutations and changes in 
gene expression.  Many genes have been implicated as promising biomarkers for 
Barrett's oesophagus.  Molecular markers of particular interest would be those that 
improve diagnostic reliability, risk stratification and/or provide molecular targets for 
intensified surveillance and treatment.  Identification of genetic risk factors underlying 
the metaplasia-dysplasia-adenocarcinoma sequence of Barrett’s oesophagus in 
relation to environmental factors, may allow the development of an individualised risk 
reduction intervention strategy.  The selection of the genes analysed in our study 
population was based on the understanding that complex conditions such as 
Barrett’s oesophagus may develop as a consequence of interaction between genetic 
risk factors triggered by environmental factors. 
 
The cyclo-oxygenase 2 (COX-2) (Morris et al. 2001; Shirvani et al. 2000), c-myb 
(Brabender et al. 2001) and c-myc (Tselepsis et al. 2003)  genes were included in 
the study based on the fact that their mRNA expression is known to increase early,   
progressively and significantly through the stages of Barrett’s metaplasia to OAC.  
Furthermore, inhibition of gene expression can decrease cell growth and increase 
apoptosis in vitro in oesophageal adenocarcinoma cell lines (Souza et al. 2000).  
The iron-related gene c-myc, and also the natural resistance-associated 
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macrophage protein-1 (NRAMP1 / SLC11A1), were included because of the role of 
iron in oxidative stress, implicated in the development of BO and OAC.  c-Myc is 
regulated by iron and represses NRAMP1 / SLC11A1, which in turn modulates the 
cytoplasmic iron pool (Bowen et al. 2002).  Analysis of TP53 was included as 
mutations resulting in protein over expression that is detectable by immuno-
histochemistry (Lane and Benchimol 1990), may represent the most common 
genetic event in human malignancy.  The likelihood that single biomarkers would be 
of limited predictive value in Barrett’s oesophagus led to the multi-gene approach.  
The COX-2, c-myb, c-myc, NRAMP1/SLC11A1 and TP53 genes selected for 
analysis this study have not previously been studied in the South African patient 
cohort for prognostication purposes. 
 
Many questions remain unanswered about Barrett's oesophagus.  Will biomarkers 
indicating increased risk help us stratify patients by individual risk and will any 
treatment, be it medical, ablative, or surgical, have any effect on the natural history 
of this disease? Why does only a small subset of patients with GORD develop 
Barrett's oesophagus and OAC, as experienced in the local population? Answers to 
these and other questions are eagerly awaited and some are provided in this study.   
 22
  
CHAPTER 2 
 
LITERATURE OVERVIEW 
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Barrett’s oesophagus is an intermediate lesion lying along the continuum linking 
normal epithelium to adenocarcinoma and is related to chronic gastro-oesophageal 
reflux disease.  The malignant potential of Barrett’s oesophagus is specifically 
conferred by the presence of intestinal or specialised metaplasia as the defining 
hallmark.  Much attention has been focused on understanding the molecular biology 
of the Barrett’s precursor lesion in the hope that this knowledge will eventually 
culminate in earlier detection and more effective treatments.  Several new 
biomarkers that have been recently evaluated can potentially also help to identify a 
group of patients with an increased risk of developing high-grade dysplasia (HGD) 
and cancer.  As yet, none of the molecular markers has shown to be a better 
predictor or more cost effective than the finding of dysplasia on biopsy.   
 
2.1 Epidemiology and Clinical features 
 
2.1.1 Epidemiology 
 
Barrett’s oesophagus is found in approximately 6–12% of patients undergoing 
endoscopy for symptoms of chronic GORD (Sarr et al. 1985; Cameron et al. 1992).  
The mean age at the time of diagnosis is approximately 55 years (Spechler 1996).  
Although this affects children, it is rare before the age of five (Hassall 1997).  This 
observation supports the contention that Barrett's oesophagus is an acquired and 
not a congenital condition.  Barrett's oesophagus appears to be uncommon in blacks 
and Asians (Spechler et al. 2002).  In a South African study with a 5:1 black to white 
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ratio in the population, only 5% of 216 consecutive patients diagnosed with Barrett’s 
oesophagus between 1970 and 1993 were black (Mason et al. 1998).  In addition to 
white ethnicity, other established risk factors for adenocarcinoma in Barrett's 
oesophagus include male gender, obesity, advanced age and long duration of 
GORD symptoms (Sampliner 2002). 
 
A familial form of Barrett’s oesophagus has been described in the setting of families 
with increased gastro-oesophageal reflux.  Sometimes the latter appears to be 
inherited as a monogenetic trait, which increases the risk of developing Barrett’s 
adenocarcinoma (Jochem et al. 1992). 
 
2.1.2 Clinical Features 
 
Clinically, the symptoms such as heartburn, regurgitation, and dysphagia of Barrett's 
oesophagus may be no different than those of conventional GORD uncomplicated by 
columnar metaplasia (Bonelli 1993).  Among patients who have endoscopic 
examinations because of chronic GORD symptoms, long segment (> 3 cm) Barrett's 
oesophagus could be found in 3 to 5 percent, whereas 10 to 15 percent have short-
segment (< 3 cm) Barrett's oesophagus (Winters et al. 1987; Spechler 2002). 
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2.2 Pathophysiology 
 
2.2.1 The role of Acid and Bile 
 
Acid and bile in the gastro-oesophageal refluxate play a key role in the pathogenesis 
of Barrett’s oesophagus in a setting of chronic exposure of the oesophagus to 
noxious stimuli.  There is a correlation between the length of Barrett's mucosa and 
the duration of oesophageal acid exposure (percent of total time that oesophageal 
pH is <4) and supine reflux (Fass et al. 2001; Spechler 1996).  The pattern of acid 
secretion may be an important determinant in the neoplastic progression of Barrett's 
metaplasia.  An ex vivo study demonstrated that pulsed acid exposure increased cell 
proliferation, but continuous acid exposure decreased cell proliferation (Fitzgerald et 
al. 1996).  Other studies have demonstrated that patients with longstanding and 
severe reflux symptoms are at increased risk of adenocarcinoma of the oesophagus 
(Lagergren et al. 1999). 
 
The response to chronic inflammation in a susceptible individual facilitates the 
transformation of the squamous oesophageal lining through the process of 
metaplasia, in which one kind of fully differentiated (adult) cell replaces another via 
key molecular alterations (Spechler et al. 1996).  The metaplastic columnar cells of 
Barrett's oesophagus are, in some ways, a favourable adaptation to chronic reflux 
since they appear to be more resistant to reflux-induced injury than the native 
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squamous cells.  Unfortunately, oesophageal columnar metaplasia predisposes to 
the development of adenocarcinoma (Morales et al. 2002). 
 
Given the propensity for severe GORD in patients with long segment Barrett's 
oesophagus, it was initially assumed that the metaplasia progressed in extent over 
the years, as columnar epithelium replaced more and more reflux-damaged 
squamous epithelium.  However, for reasons that are unclear, such progression is 
observed only rarely (Cameron and Lomboy 1992).  In most cases, Barrett's 
oesophagus appears to develop to its full extent over a short period of time (i.e.  <1 
year), with little or no subsequent progression.  Why this occurs is not well 
understood. 
 
Patients with short-segment Barrett's oesophagus often have few or no symptoms 
and signs of GORD.  The development of intestinal metaplasia in patients with short-
segment disease may be due to exposure to noxious agents that accumulate at the 
gastro-oesophageal junction (GOJ).  After meals, there is a pocket of acid at the 
GOJ that escapes the buffering effects of ingested food (Fletcher et al. 2001).  This 
postprandial acid pocket has a mean length of 2 cm, beginning in the most proximal 
stomach, and extending more than 1 cm above the squamo-columnar junction (Z-
line) into the distal oesophagus.  In healthy volunteers, the very distal oesophagus (5 
mm above the Z-line) is exposed to acid for more than 10 percent of the day 
(Fletcher et al. 2004). 
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Potential consequences of such persistent acid exposure include not only acid-peptic 
injury, but also exposure to high concentrations of nitric oxide (NO) generated from 
dietary nitrates (NO3) in green, leafy vegetables.  Most ingested nitrate is absorbed 
by the small intestine and excreted unchanged in the urine, but approximately 25 
percent is concentrated by the salivary glands and secreted into the mouth, where 
bacteria on the tongue reduce the recycled nitrate to nitrite (NO2).  When swallowed, 
nitrite encounters acidic gastric juice: the nitrite is converted rapidly to nitric oxide 
(NO).  After nitrate ingestion, high levels of NO have been demonstrated at the GOJ 
(Iijima et al. 2002).  NO can be genotoxic, and potentially carcinogenic.  Thus, the 
GOJ is exposed repeatedly to acid, pepsin, NO, and other noxious agents in gastric 
juice that can lead to chronic inflammation and metaplasia. 
 
2.2.2   The role of Helicobacter pylori infection  
 
Gastric infection with H. pylori causes chronic inflammation that can result in 
intestinal metaplasia and cancer in the stomach (Chow et al. 1998).  However, the 
organism does not infect the oesophagus and there is no positive association 
between H.  pylori infection and GORD.  Indeed, a number of studies suggest that H.  
pylori infection may protect the oesophagus from GORD and its complications like 
Barrett's oesophagus, perhaps by causing a chronic gastritis that interferes with acid 
production (Graham et al. 1998).  H. pylori strains that express cytotoxin-associated 
gene A (cagA) appear to be especially damaging to the stomach, and especially 
protective towards the oesophagus (Vaezi et al. 2000). 
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Segal (2001) reviewed the epidemiological and clinical studies that have reported on 
GORD, Barrett’s oesophagus, OAC and H. pylori infection in sub-Saharan Africa.  
The data indicates that Barrett’s oesophagus is rare and OAC uncommon in all 
regions of sub-Saharan Africa studied (South Africa, Ethiopia, Nigeria, Zimbabwe, 
Kenya and Uganda).  Similarly, hiatus hernia is also uncommon.  The overwhelming 
majority of oesophageal cancers are squamous in type.  H. pylori infection is 
ubiquitous with an overall prevalence of 61-100%.  It was concluded that although 
urbanisation has resulted in an increase of risk factors associated with GORD, which 
would be expected to lead to an increase in this disease among Africans, this 
increase has not occurred.  It is believed that the critical factor preventing GORD in 
black Africans is H. pylori infection, which is usually acquired in childhood, is for life 
and is probably protective for the oesophagus. 
 
2.3 Morphology of Barrett’s oesophagus 
2.3.1 Macroscopic features 
Glandular mucosa in the lower oesophagus presents as a red velvety mucosa over 
the gastro-oesophageal junction.  It can extend either circumferentially or as one or 
several tongues, and in some cases as a mixture of these two patterns.  Until 
recently, it was considered that this mucosa had to extend at least 30 mm above the 
gastro-oesophageal junction to diagnose Barrett’s oesophagus.  But this definition 
has changed, owing to the recognition of short segment Barrett’s oesophagus 
measuring less than 30 mm (Spechler et al. 1996; Sharma and Sampliner 1998).  
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However, as it may be difficult to accurately measure a short segment Barrett’s 
oesophagus and to localise the metaplastic mucosa and the gastro-oesophageal 
junction, it is now well recognised that the major diagnostic criteria of Barrett’s 
oesophagus is histological.  The significance of intestinal metaplasia discovered on 
biopsies taken from an endoscopically normal junction (sometimes considered as an 
"ultra short" Barrett’s oesophagus) remains controversial, and will not be discussed 
in this text.   
2.3.2 Histological features 
 
Traditionally, three types of columnar epithelia have been described in Barrett's 
oesophagus, namely cardiac, gastric fundic-type and specialised intestinal 
metaplasia (Paull et al. 1976).  Specialised intestinal metaplasia is the most common 
and also the only type that specifically confers the malignant potential of Barrett’s 
oesophagus (Spechler 2002).  Most authorities insist on the demonstration of 
specialised intestinal metaplasia to confirm an endoscopic diagnosis of Barrett's 
oesophagus.  Morphologically, it frequently shows a villiform pattern.  The epithelium 
is composed mainly of goblet cells interspersed between intermediate mucous cells, 
both in the surface and glandular epithelium.  Mature absorptive intestinal cells with a 
well defined brush border are rare.  Paneth cells may be present, but they are as 
rare as in incomplete intestinal metaplasia of the gastric mucosa.  Endocrine cells 
can be seen on special staining in the glands.  On electron microscopy, the goblet 
cells have characteristic apical mucin granules, and the columnar mucin cells have 
features intermediate between gastric mucous cells and intestinal absorptive cells 
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(Zwas et al. 1986).  The presence of goblet cells is the most useful feature for 
distinguishing specialised intestinal metaplasia from gastric cardiac or fundic-type 
mucosa.   
2.3.2.1 Mucin histochemistry 
Mucins are produced by both columnar mucinous and goblet cells and can be 
characterised by mucin histochemistry.  The columnar cells may produce neutral 
mucins, similarly to gastric surface epithelial cells, and/or acidic mucins, typical of 
intestinal mucosa.  Therefore, these cells can stain red (neutral mucins), blue (acidic 
mucins), or magenta (neutral and acidic mucins) on a combined PAS–alcian blue 
stain (Peuchmaur et al. 1984; Rothery et al. 1986).  Although it has been suggested 
that the presence of acidic mucins (blue on alcian blue) is a characteristic feature of 
Barrett’s oesophagus in the absence of typical goblet cells, this theory has been 
disputed by other studies that showed alcian blue positive columnar cells in gastric 
cardiac surface or neck cells in patients with neither metaplasia of the lower 
oesophagus nor gastro-oesophageal reflux disease (Genta et al. 1994; Chen et al. 
1999b).   
The presence of goblet cells is the only characteristic feature of intestinal Barrett’s 
mucosa.  These cells produce in all cases acid mucins that are usually easily 
visualised on routinely stained sections.  Therefore, routine staining of biopsies of the 
gastro-oesophageal junction with alcian blue may only be of value in demonstrating 
rare positive goblet cells, which may indicate short segment Barrett’s oesophagus.   
Acidic mucins can be divided into sialomucins and sulfomucins.  On a combined high 
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iron diamine–alcian blue stain, sialomucins stain blue, and sulfomucins stain brown–
black.  In specialised Barrett’s mucosa, goblet cells usually contain both sulfomucins 
and sialomucins.  The presence of sulfomucins in columnar cells is a characteristic 
feature of type III intestinal metaplasia of the stomach, a lesion with a premalignant 
potential.  In Barrett’s oesophagus, it is very common to have sialomucin containing 
columnar cells, a feature that shows that this pattern cannot be used to delineate a 
population at high risk of malignancy (Peuchmaur et al. 1984; Rothery et al. 1986). 
2.3.2.2 Immuno-histochemistry 
For practical purposes, intestinal metaplasia of the oesophagus and the cardia can 
usually be distinguished by routine histology, but as immuno-histochemistry is now 
routinely used in almost all pathology departments, numerous studies have tried to 
find sensitive and specific markers of intestinal type mucosa in the oesophagus.  
These markers include the MUC antigens and other mucin components, and different 
cytokeratin (CK) subtypes.   
Cytokeratins are the intermediate filaments characteristic of epithelial cells.  There 
are 20 distinct subtypes, with the pattern of expression depending on the type and 
origin of the epithelium.  As the characteristic pattern is conserved in most 
carcinomas, CK 20, a marker of intestinal differentiation, and CK 7, a marker of 
ductal differentiation, are routinely used in the diagnosis of poorly differentiated 
carcinomas.  Immuno-histochemical studies, using monoclonal anti-bodies to CK 7 
and 20, have been reported to make it possible to differentiate accurately between 
intestinal metaplasia originating from either the oesophagus or cardia of the stomach 
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(Ormsby et al. 2000).  In oesophageal intestinal metaplasia, CK 7 positivity is found 
in superficial and deep glands, whereas CK 20 positivity is limited to superficial 
glands only (Barrett’s CK 7/20 pattern).  This sensitive and specific Barrett CK 
pattern has been observed in both long and short segment Barrett’s oesophagus, 
and even in ultra short segment Barrett’s oesophagus (Ormsby et al. 2000; 
Couvelard et al. 2001).  In cardiac type intestinal metaplasia, CK 7 immuno-reactivity 
is absent (or weak or patchy), but CK 20 positivity is seen in superficial and deep 
glands.  Although earlier reports suggest that CK 7/20 immuno-staining patterns are 
useful clinically, routine application of these immuno-histochemical techniques is 
controversial and should be used in conjunction with current endoscopic and 
histological findings (El-Zimaity et al. 2001; Mohammed et al. 2002).  Similar results 
have been obtained with antibodies reacting with intestinal goblet cells, such as Das1 
antibody (DeMeester et al. 2002) 
 
Other antibodies have also been used to characterise intestinal metaplasia of 
Barrett’s oesophagus, directed against MUC mucin gene products, especially MUC1 
and MUC2 (an intestinal mucin).  These studies have demonstrated aberrant 
expression of MUC2 in Barrett’s intestinal mucosa which is lost when the cells 
become neoplastic.  MUC1 was absent in metaplastic and dysplastic epithelium, but 
was expressed in carcinomas, which suggests that it could differentiate dysplasia 
from carcinoma in mucosal biopsies (Chinyama et al. 1999; Guillem et al. 2000).   
Molecular studies, in addition to the morphologic and immuno-histochemical features 
of intestinal metaplasia discussed above, further support the specialised cellular 
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differentiation of Barrett’s mucosa.  Sucrase-isomaltase, an intestinal disaccharide, is 
expressed in 76% of Barrett’s mucosa, where it is localised to the apical membrane, 
and 82% of oesophageal adenocarcinomas, where immuno-histochemistry 
demonstrated a diffuse pattern (Wu et al. 1993).   
 
2.3.2.3 Dysplasia 
 
Cancers in Barrett's oesophagus evolve through a sequence of DNA alterations that 
give the cells certain growth advantages, and cause morphological changes in the 
tissue that the pathologist can recognise as dysplasia.  Dysplasia has been defined 
by Riddell et al. (1983) as an unequivocal neoplastic epithelium strictly confined 
within the basement membrane of the gland from which it arises.  Although this 
definition was initially proposed for premalignant changes developing in inflammatory 
bowel disease, it has been progressively extended to the entire gastrointestinal tract, 
including Barrett’s oesophagus (Schmidt et al. 1985).  Dysplasia as a premalignant 
lesion is strictly synonymous to intraepithelial neoplasia, a term in use in most organs 
including the gynaecological tract, and has been recommended for use in Barrett’s 
oesophagus by the World Health Organization (Werner et al. 2000).  Dysplasia has 
to be distinguished on both ends of the morphological spectrum of changes, from 
regenerative non-neoplastic modifications, often called atypia, and from invasive 
cancer, especially in its early or superficial form with invasion limited to the lamina 
propria.   
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Dysplasia is a constellation of histological abnormalities suggesting that one or more 
clones of cells have acquired genetic damage, rendering them neoplastic and 
predisposed to malignancy (Spechler 2001).  Pathologists diagnose dysplasia when 
they recognise a constellation of characteristic cytological and architectural 
abnormalities in tissue biopsy specimens.  Architectural changes include glandular 
distortion and crowding.  Papillary extensions may be present in gland lumen, and 
villiform configuration of the mucosal surface can be observed.  Cytological changes 
include nuclear alterations such as variation in size and shape, nuclear and/or 
nucleolar enlargement, increased nuclear to cytoplasmic ratio, hyperchromsia, and 
increased number or abnormal mitoses.  Most authors consider that these changes 
have to involve the mucosal surface to warrant the diagnosis of dysplasia.  (Geboes 
et al. 2000; Riddell et al. 1983;) 
 
Based on the degree of alteration in nuclear morphology and glandular architecture, 
dysplasia is classified into grades of increasing severity.  Although a three tiered 
classification (mild–moderate–severe) is still in use in some centres, most 
pathologists use a two tiered system that distinguishes between low grade dysplasia 
(LGD) and high grade dysplasia (HGD).  In this two grade system, LGD includes the 
mild and moderate categories of the three grades’ system.  Generally, low-grade 
dysplasia is distinguished from high-grade dysplasia based on nuclear localisation in 
relation to the luminal surface of the cell.  The Riddell’s classification of dysplasia 
also includes a category of mucosa indefinite for dysplasia.  The term carcinoma in 
situ (or intraepithelial carcinoma) is not used in the Riddell’s classification, as it is 
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considered indistinguishable from HGD.  In intramucosal carcinoma, neoplastic cells 
have penetrated through the basement membrane and infiltrate into the lamina 
propria, leading to a small risk of regional lymph node metastasis. 
 
Unfortunately, dysplasia is an imperfect marker for malignancy because of inter-
observer disagreement in grading its severity, biopsy sampling error and incomplete 
data on natural history.  Among experienced pathologists, inter-observer agreement 
for the diagnosis of low-grade dysplasia in Barrett's oesophagus is less than 50 
percent and for high-grade dysplasia approximately 85 percent (Reid et al. 1988; 
Skacel et al. 2000; Montgomery et al. 2001).  Given the progressive and subtle 
changes that occur from non-dysplastic to LGD to HGD, it is not surprising that this 
variation exists.  In the "expert" study by Montgomery et al. (2001), the diagnoses 
made by 12 senior gastrointestinal pathologists on 125 biopsies were compared.  
When a four grade system was employed (non-dysplastic/indefinite, low grade, high 
grade and cancer), the kappa index was low (0.43).  Kappa improved (0.66) when a 
simplified classification was used (non-dysplastic/indefinite and low grade/high grade 
and cancer).  In a study involving 20 general pathologists in the USA (Alikhan et al. 
1999), there was very large variation in the diagnoses of non-dysplastic mucosa, 
LGD, and HGD.  These results emphasise the need to obtain a second opinion on 
difficult cases, especially when a therapeutic decision has to be made.  Furthermore, 
dysplastic changes should be interpreted with caution when atypical epithelial cells 
(arising from the background of active inflammation) are present.    
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2.3.2.4 Natural history of dysplasia
 
Barrett’s adenocarcinomas seem to develop by a multi-step process, recognised 
histologically as the metaplasia-dysplasia-adenocarcinoma sequence (Jankowski et 
al. 1999).  When patients included in surveillance cohorts are considered, it has been 
well established that the presence of dysplasia indicates an increased risk of 
carcinoma.  However, the natural history of this lesion is still very difficult to predict 
for one individual patient (Goldblum et al. 2002).  HGD is the nearest precursor of 
adenocarcinoma, as shown by association with cancer in surgical specimens, and 
prior to the development of cancer in surveillance programmes.  It must be 
remembered that dysplasia detected on endoscopic biopsies is also frequently a 
marker of synchronous carcinoma, as in most surgical series up to 40% of Barrett’s 
oesophagus resected for HGD have an occult adenocarcinoma (Heitmiller et al. 
1996; Falk et al. 1999).  The frequency of these unsuspected cancers varied upon 
the endoscopic and biopsy protocol, with very few cancers detected when patients 
were followed using the "Seattle" protocol (four quadrant biopsies at 1 cm intervals) 
at closely timed intervals (Levin et al. 1993). 
 
The natural history of HGD is still a matter of debate.  In two large series that 
included 145 patients with HGD, although the risk of malignant transformation was 
relatively high, the majority of patients did not progress to adenocarcinoma after 
several years of follow up (Schnell et al. 2001; Levine et al. 1996).  In these two 
studies, after the initial diagnosis of HGD, 25% and 16% of patients developed 
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carcinoma after a mean surveillance period of 2.5 years and 7.3 years, respectively.  
When considering these series, it can be concluded that HGD does not progress to 
adenocarcinoma in the majority of patients within some years, and that non-surgical 
procedures (surveillance and endoscopic treatments) can be considered as 
reasonable options in those patients - a statement that is still very much debated in 
the literature (Goldblum et al. 2002).  It is interesting to note that in one of these two 
series, there was an unusually high proportion of Barrett’s oesophagus patients with 
LGD (737 of 1099, 67%), and the histological diagnoses were made during a period 
of 20 years by one experienced pathologist (Schnell et al. 2001).   
 
Recently, the distinction between unifocal and multifocal HGD has been emphasised 
by Weston et al. (2000), with a high rate of progression from unifocal to multifocal 
HGD or invasive carcinoma (8 of 15 patients within a mean follow up period of 37 
months).  Similarly, another study demonstrated that the risk of malignant 
progression increased by 3.7 when diffuse HGD was present (Buttar et al. 2001).  
These findings have recently been challenged by Dar et al. (2003).  It has also been 
shown that the presence of endoscopic polypoid lesions [an equivalent of DALM 
(Dysplasia Associated Lesion or Mass) in inflammatory bowel disease] was an 
indicator of high risk of cancer (Thurberg et al. 1999).   
 
The natural history of LGD is even less defined.  This could be at least partially due 
to the poor diagnostic reproducibility of this lesion.  It was considered traditionally 
that LGD was a very slowly progressing lesion.  In most series, there was even a 
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high rate of apparent regression from LGD to non-dysplastic mucosa reported.  This 
last phenomenon has several potential explanations: initial over diagnosis of LGD, 
due to the difficulty in differentiating reactive from dysplastic changes; sampling 
variability; or real neoplastic regression.  However, this opinion about the benign 
course of LGD has been challenged in some recent studies.  In a study based on a 
multi centre pathological recruitment of 26 cases with a diagnosis of LGD, 4 patients 
(15%) developed HGD and 4 (15%) an adenocarcinoma, 2 – 65 months after the 
initial diagnosis of LGD.  In another study, 7 patients (28%) developed HGD (5 
patients) or an adenocarcinoma (2 patients) after a mean follow up of 26 months 
(range 2 – 43 months) after the diagnosis of LGD (Skacel et al. 2000).  Very 
interestingly, in this latter study all cases were reviewed blindly by 3 gastrointestinal 
pathologists.  When all 3 pathologists agreed on the initial diagnosis of LGD, 4 of 5 
patients progressed to a more severe lesion, while none of the 8 patients with no 
agreement for the initial diagnosis progressed.   
 
2.3.3 Adenocarcinoma arising from Barrett’s oesophagus 
 
Barrett's oesophagus is thought to be the precursor of adenocarcinoma of the 
oesophagus and of the gastro-oesophageal junction (GOJ).  Adenocarcinomas that 
straddle the GOJ are approximately twice as common as adenocarcinomas that 
clearly arise from the oesophagus (Cameron et al. 1995).  With straddling tumours, it 
can be difficult to determine whether the neoplasm arose from the columnar 
epithelium in the distal oesophagus or in the proximal stomach (the gastric cardia).  
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These tumours cannot be distinguished from one another morphologically, and they 
share a number of epidemiologic features including an association with GORD, a 
strong predilection for white males, and a rapidly rising incidence in Western 
countries (Cameron et al. 1995). 
 
Biochemical studies are also consistent with the hypothesis that Barrett's 
oesophagus is the precursor for most GOJ tumours.  In one series, for example, 
similar profiles of intestinal-type proteins were detected by immuno-fluorescence 
microscopy in Barrett's oesophagus and in 26 cases of adenocarcinoma with or 
without obvious Barrett's in tumours from both oesophagus and cardia (Mendes de 
Almeida et al. 1997).  These profiles were not seen in normal stomach or 
oesophageal mucosa, reflux oesophagitis or squamous cell carcinoma. 
 
2.4 Mechanisms of malignant transformation  
Human tumours are thought to arise as a multi-step process, modulated by genetic 
and environmental factors.  The accumulation of genetic alterations leads to genomic 
instability and through complex interactions between stimulatory oncogenes and 
regulatory tumour-suppressor genes, results in widespread clonal outgrowth of cells 
exhibiting aberrant cell cycle regulation, with the capacity for invasion (Hanahan and 
Weinberg 2000).  Generally, genomic instability precedes the appearance of 
histological changes.  More specifically, cancers in Barrett's oesophagus evolve 
through a sequence of genetic alterations in which the metaplastic cells acquire the 
ability to proliferate without exogenous stimulation, to resist growth-inhibitory signals, 
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and to avoid triggering the programmed death mechanism (apoptosis) that ordinarily 
destroys cells that acquire extensive genetic damage.  Many of the genetic changes 
that endow cancer cells with these growth advantages do so by affecting 
components of the cell cycle clock apparatus, the pivotal molecular machinery in the 
cell nucleus that controls whether a cell will proliferate, differentiate, become 
quiescent or die. 
2.4.1 Cell-cycle kinetics  
 
Neoplasia is the ultimate result of disruption of the normal cell cycle.  The normal cell 
cycle comprises several well-defined stages.  Progression through each stage is 
modulated by complex interactions between stimulatory and inhibitory signals 
mediated by oncogenes and tumour-suppressor genes respectively.  Quiescent cells 
(stage G0) enter the cell cycle in the G1 (first gap) phase and progress under 
external mitogenic stimulation to S phase, in which DNA synthesis occurs.  The cell 
now is committed to divide irrespective of exogenous factors, and after proceeding 
through G2 (second gap), enters M phase were mitoses occurs.  The RNA and 
proteins needed for DNA replication are synthesized during the G1 phase.  There is 
a critical point, late in the G1 phase, where a decision is made either to continue and 
complete the cell cycle, or to exit the cycle.  This critical juncture is called the 
'restriction point' (R-point) (Pardee 1974).  DNA replication does not proceed until the 
S phase, during which the cell's DNA content doubles, increasing from the diploid 
value of 2n to the fully replicated, tetraploid value of 4n.  During the G2 phase, the 
tetraploid cell prepares for the upcoming mitotic division.  Finally, in M phase the cell 
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divides into two daughter cells, each containing a diploid (2n) complement of DNA.  
After mitosis, cells may withdraw from the cell cycle to enter a quiescent state 
termed G0.  Under certain conditions, such cells can be stimulated to leave the G0 
phase and re-enter the cell cycle. 
 
The cell cycle is regulated at key checkpoints (G1/S and G2/M) by cyclins and cyclin-
dependent kinases (cdks), which interact with cellular proteins to activate 
transcriptional factors having positive and negative regulatory effects.  For example, 
the cyclin D1/cdk-4 (or cdk-6) complex regulates the early to mid-G1 phase, after 
phosphorylation of the retinoblastoma (Rb) tumour-suppressor protein, the E2F 
transcription factor activates genes required for DNA synthesis in S phase, driving 
the cell to G1/S transition.  Whereas the p16 tumour-suppressor gene inhibits 
association of cdk-4 (and cdk-6) with cyclin G1, mutational activation of ras 
oncogenes induces cyclin D1 expression (Filmus et al. 1994).  This regulatory 
process is modulated further by interactions with other upstream and downstream 
genes.  The TP53 tumour-suppressor gene may induce cell-cycle arrest by 
transcriptional activation of p21 (WAF-1), which sequesters various cdks (El-Deiry et 
al. 1993; Kirsch et al. 1998).  Therefore, progression through the G1/S checkpoint 
may result from the loss of Rb, p16, or TP53 or by over expression of ras or cyclin 
D1.   
 
A reciprocal relation among Rb, cyclin D1 and p16 expression has been reported in 
oesophageal cancer.  In general, tumours that retain Rb expression typically exhibit 
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over expression of cyclin D1, p16 inactivation, or both, often in the context of TP53 
mutations (Schrump et al. 1996). 
 
2.4.2 Increased proliferation  
 
Immuno-histochemistry and flow cytometry have been used to study cell proliferation 
in oesophageal tissues, evaluating distribution of proliferating cell nuclear antigen 
(PNCA) and Ki67 (Hong et al. 1995; Jankowski et al. 1992; Whittles et al. 1999).   
PCNA is an indicator of cell cycle progression at the G1/S transition, and Ki67 is 
expressed in proliferating cells (G1, S, G2, and M phases).  Whereas PCNA 
immunostaining normally is seen in the basal layer of metaplastic Barrett’s 
epithelium, the immunoreactivity is seen to extend superficially with high-grade 
dysplasia.  Immuno-histochemical studies with the monoclonal antibody MIBI-1 
(against Ki67) demonstrated a higher percentage of proliferating cells in metaplastic 
Barrett’s mucosa compared with normal gastric epithelium.  Staining patterns for low- 
and high-grade dysplasia were similar to PCNA, suggesting a greater turn-over of 
differentiated cells in the surface epithelium by immature proliferating cells arising 
from basal layers.   
 
Increased proliferative activity and the altered cell-cycle kinetics also have been 
shown with flow cytometry in Barrett's epithelium.  An increased G1 fraction seems 
the earliest finding, progressing to increased S-phase fractions with aneuploidy, 
high-grade dysplasia, and carcinoma (Chanvitan et al. 1995; Reid et al. 1992; Reid 
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et al. 1996).  These findings suggest a functional instability of Barrett’s mucosa, 
predisposing to increasing dysplasia and malignancy. 
 
2.4.3  DNA content 
 
2.4.3.1 Changes in DNA content 
 
Systematic flow cytometry can identify patients with increased 4n or aneuploidy and 
has also been used in recent studies.  Abnormalities in DNA content occur early and 
often in Barrett’s epithelium.  Initial studies laying the groundwork for molecular 
studies in Barrett’s oesophagus focused on abnormal DNA content known as 
aneuploidy.  Flow cytometry has proven valuable in this context and aids in detecting 
clonality within tissues and cells which in turn characterises early development of 
genomic instability (Nowell et al. 1976).  This paradigm has been validated in earlier 
studies showing that aneuploidy or increased tetraploidy (4n) populations occur in 
more than 90% to 95% of Barrett’s-associated cancers, arise in premalignant 
Barrett’s epithelium, and predict progression (Reid et al. 1992; Reid et al. 1987; 
Galipeau et al. 1996, Barrett et al. 1999).  One earlier study suggested that 
alterations in ploidy correlated with dysplasia in Barrett’s oesophagus (James et al. 
1989).  Some patients with questionable dysplasia in this study were also found to 
have altered DNA ploidy (Reid et al. 1987).  In another series of patients, the 
presence of aneuploid cells on flow cytometric analyses of histologically equivocal 
biopsies allowed identification of areas of mild dysplasia.  Furthermore, aneuploidy 
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was always associated with some morphological abnormality; varying from mild 
dysplasia to frank carcinoma (James et al. 1989).  Further studies subsequently 
emerged asserting that aneuploidy may serve as an adjunct in identifying patients 
with Barrett’s oesophagus who were more likely to progress to dysplasia (Reid et al. 
1992, Fennerty et al. 1989).  A 28% 5-years’ cumulative oesophageal cancer 
incidence was found in those Barrett’s patients with either aneuploidy or increased 
4n compared to a 0% 5-year cumulative oesophageal cancer incidence in patients 
with neither aneuploidy nor increased 4n fractions (Reid et al. 2000). 
 
Others found that aneuploidy and dysplasia can occur discordantly (Fennerty et al. 
1989).  In a seminal study of DNA ploidy in systematically mapped Barrett’s 
epithelium, clonal growth similar to that seen in fully developed cancer was present 
in metaplastic Barrett’s mucosa (Raskind et al. 1992). 
 
2.4.3.2 Chromosomal Abnormalities 
 
In several studies that have addressed specific chromosomal alterations in Barrett’s 
oesophagus, diverse karotypic abnormalities have been documented.  This includes 
Y chromosome loss, trisomies, and translocations of chromosome 7 and 11, as well 
as over presentation of chromosome 8 and loss of chromosome 17 (Garewal et al. 
1989, 1990; Haung et al. 1992).  A report evaluating chromosomal abnormalities in 
oesophageal adenocarcinoma noted gains of chromosomes 12 (eight cases), 6 
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(seven cases), and 11 (six cases).  The total number of chromosomal abnormalities 
varied from 0 to 10, with an average of 4.6 per case (Persons et al. 1981). 
 
2.4.3.3 Loss of Heterozygosity 
 
During the process of cancer evolution, molecular events that lead to a growth or 
survival advantage result in clonal expansion.  Moreover, normal DNA repair 
mechanisms check replication fidelity before permitting progression through 
subsequent stages of the cell cycle.  Deletions and other DNA alterations permit 
unhampered progress through the cell cycle, leading to proliferation and expansion 
of abnormal or mutated clones of cells. 
 
Studies have reported varying frequencies of LOH involving multiple chromosomal 
loci in Barrett’s oesophagus.  One of the earliest regions investigated was 
chromosome 17p13.1, the locus of the TP53 tumour suppressor gene.  The 17p 
LOH was detected in 52% to 93% of Barrett’s associated oesophageal 
adenocarcinoma (Blount et al. 1991).  Furthermore, 17p allelic loss was found to 
precode 5 q allelic loss in patients with Barrett’s and high-grade dysplasia or 
adenocarcinoma (Blount et al. 1993).   
 
Evidence has been presented that allelic loss of 9p21 and point mutations of the p16 
gene develops as early lesions during neoplastic progression in Barrett’s 
oesophagus (Barrett et al. 1996).  However, one study showed that deletions of loci 
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harbouring the TP53, p16, and APC genes were infrequent in patients with Barrett’s 
oesophagus without dysplasia but were evident in adenocarcinomas arising in 
Barrett’s oesophagus (Gonzales et al. 1997).  Particularly interesting is a recent 
report suggesting that deletion of a locus (31-32.1) on chromosome 14q can be used 
to differentiate adenocarcinomas of the oesophagus versus gastric cardia origin (Van 
Dekken et al. 1999).  These findings suggest that deletions of these important 
tumour genesis genes may constitute later neoplastic events. 
 
2.4.4 Tumour-suppressor genes  
 
The products of tumour-suppressor genes prevent the acquisition of the transformed 
phenotype in vivo.  Loss of function results in tumour development. 
 
2.4.4.1 TP53 
 
The tumour-suppressor gene TP53 encodes a 53-kd polypeptide that regulates cell-
cycle progression, DNA repair, apoptosis, and neo-vascularisation in normal and 
malignant cells by means of highly complex DNA and protein interactions (Prives 
and Hall 1999).  TP53 mediates cell-cycle arrest in part by inducing the expression of 
p21 (WAF-1), which sequesters various cdks facilitating G1and G2 /M arrest (El-
Deiry et al. 1993).  When the DNA of normal cells sustains damage during G1, TP53 
protein rapidly accumulates to halt any further progression of the cell cycle (Giaccia 
and Kastan 1998).  This period of cell cycle arrest allows time for the intrinsic DNA 
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repair mechanisms to correct the genomic damage before the mutation can be 
perpetuated by DNA replication during S phase.  One means by which the tumour 
suppressor TP53 halts cell cycle progression is by inhibiting the actions of cyclins D1 
and E, thereby preventing the phosphorylation of Rb protein that allows 
advancement to S phase.  If the cell is able to repair its damaged genome, TP53 
levels return to baseline values, cyclins D1 and E are no longer inactivated, and the 
cell can proceed through the R-point (Kastan et al.1991).  If a cell loses its normal 
TP53 function, then DNA damage might not be repaired in G1, and the mutation can 
be perpetuated.  If the mutation endows the cell with growth advantages, 
carcinogenesis may result.   
 
Frequent point mutations of TP53 were shown to occur in Barrett’s-associated 
adenocarcinoma and adjacent dysplasia or metaplasia (Casson et al. 1991), and 
therefore make TP53 perhaps the key tumour-suppressor gene in oesophageal 
adenocarcinoma.  Up to 70% of oesophageal cancers carry TP53 mutation and/or 
deletion (Wang et al. 1993).  Frequently LOH of the TP53 locus on 17p13.1 is seen 
not only in adenocarcinoma, but also in Barrett’s metaplasia and dysplasia (Barrett et 
al. 1999).  Recent studies have found that in individuals, who progressed from 
Barrett’s oesophagus to oesophageal adenocarcinoma, one of two normal TP53 
alleles was inactivated by mutation and the second was lost by a mechanism termed 
as loss of heterozygosity (LOH).  Reid and colleagues (2001) followed 256 patients 
with Barrett’s oesophagus and TP53 LOH data at baseline for up to 5 years and 
found TP53 LOH to be a strong predictor of progression to oesophageal 
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adenocarcinoma (relative risk 16; 95% CI 6.2 to 39; p<0.001).  However, the 
prevalence of TP53 alteration in non-dysplastic Barrett’s mucosa is relatively low 
(Gonzalez et al. 1997).  In most patients with high-grade dysplasia, the Barrett’s 
mucosa contains a mosaic of clones and sub clones with differing patterns of 17p 
LOH (Galipeau et al. 1999).   
 
In a recent study by Dolan et al. (2003) TP53 mutation analysis was performed on 
premalignant and malignant tissue from 30 patients undergoing oesophagectomy for 
adenocarcinoma, and on premalignant biopsies from 48 patients participating in a 
Barrett's surveillance program.  The mean follow-up for the patients in the 
surveillance program was 5 years.  TP53 mutations were detected in a third of the 
patients with oesophageal adenocarcinomas, and were more common in well-
differentiated carcinomas.  An identical TP53 mutation was detected in carcinoma 
and adjacent dysplasia.  Two patients with premalignant Barrett's esophagus had 
TP53 mutations and one of these patients developed adenocarcinoma on follow-up 
whilst the other has not yet progressed beyond metaplasia at the time of publication 
of their study.  No patient without TP53 mutation developed high-grade dysplasia or 
adenocarcinoma.  Similarly, in a study by Klump et al. (1999), TP53 mutations were 
detected in 33% of oesophageal adenocarcinomas and in 4% of premalignant 
Barrett's oesophagus in patients undergoing endoscopic surveillance. 
 
The role of TP53 in the malignant progression of Barrett's oesophagus has been 
studied primarily using immuno-histochemistry.  Wild-type TP53 protein is labile, has 
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a very short half-life, and normally is not demonstrable by immunostaining.  In 
contrast, mutant TP53 is often more stable, and can accumulate within the cell to the 
point that it is detectable by immunostaining.  Immunostaining for TP53 has been 
found in the non-dysplastic, specialised intestinal metaplasia of Barrett's 
oesophagus, and such staining is found with increasing frequency as dysplasia 
progresses in severity (Ramel et al. 1992; Younes et al. 1993; Flejou et al. 1993; 
Hamelin et al. 1994).  In Barrett’s oesophagus, frequencies of TP53 over expression 
correlate with the degree of dysplasia (Galipeau et al. 1999).  Furthermore, early 
dysplastic lesions with TP53 expression have been associated with a higher 
likelihood of progression to high-grade dysplasia, suggesting a value to determine 
TP53 status in patients with low-grade dysplasia (Glimenez et al. 1999).   
 
In summary, TP53 mutations can be detected before the development of high-grade 
dysplasia or carcinoma, and may be useful in stratifying the risk of adenocarcinoma 
in patients with Barrett's oesophagus.  However, low frequencies of elevated TP53 
expression in Barrett’s oesophagus without dysplasia seem to preclude its 
widespread use as a screening tool.  Futhermore, imunno-histochemistry can give 
false negative results if the TP53 mutations lead to protein truncation not detectable 
by the antibody (Fitzgerald 2005). 
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 2.4.4.2 Retinoblastoma 
 
The retinoblastoma (Rb) gene, located on 13q14, encodes a 105-kd nuclear 
phosphoprotein that ultimately is involved in regulation of the G1 restriction point 
(Chen et al. 1995b).  Loss or inactivation of both alleles of the Rb gene is the primary 
mechanism underlying retinoblastoma (Knudson et al. 1971).  Moreover, a high 
incidence of second primary tumours among patients inheriting one inactive Rb allele 
suggested that this cancer gene plays a key role in the aetiology of several other 
primary malignancies (Murphee et al. 1984).  Altered retinoblastoma mRNA 
transcript size and quantity have been demonstrated in both dysplasia and 
cancerous Barrett’s tissues (Huang et al. 1992). 
 
Oesophageal cancer cells show decreased expression of Rb protein (Coppola et al. 
1999).  Most importantly, LOH and/or abnormal mRNA transcripts involving Rb have 
been demonstrated in 36% to 67% of oesophageal tumours and, in one study, were 
associated with unfavourable survival (Wang et al. 1993).  Finally, accumulation of 
abnormal Rb protein during the progression of Barrett’s metaplasia to carcinoma 
leading to unsuppressed tumour growth has been demonstrated (Coppola et al. 
1999). 
 
 51
2.4.4.3 p16 
 
The tumour-suppressor gene p16, located on chromosome 9p21, is an inhibitor of 
the cyclin dependent kinase cdk-4 and cdk-6, preventing cyclin D-dependent 
phosphorylation of Rb protein (Grana and Reddy 1995).  A paradigm emerging from 
studies of oesophageal squamous cell carcinoma is that either cyclin D1, over 
expression or p16 inactivation seems to be required to accelerate the cell through G1 
(Klump et al. 1998).  The p16 locus undergoes frequent LOH in oesophageal cancer.  
However, relatively low frequencies of p16 inactivating mutations have been 
documented in oesophageal cancers (Esteve et al. 1996).  More recently, p16 
promoter hypermethylation has been reported in oesophageal carcinoma (Wong et 
al. 1997), suggesting that p16 (and possibly p15 as well) are the genes targeted on 
9p21. 
 
2.4.5 Proto-oncogenes 
 
Typically, oncogenes are either genes that encode a normal cellular protein that is 
expressed at inappropriately high levels or mutated genes that produce a structurally 
altered protein that exhibits inappropriate function.  The normal cellular genes from 
which the oncogenes derive are designated proto-oncogenes or cellular oncogenes.  
The protein encoded by the oncogenes comprise at least four distinct groups:  
peptide growth factors, that may be excreted in the extra cellular milieu, protein 
kinases, signal transducing proteins associated with the inner cell membrane surface 
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(membrane-associated G proteins), and transcriptional regulatory protein located in 
the nucleus (Haubruck and McCormick 1991).  Proto-oncogenes were the first major 
class of cancer-related genes to be studied.   
 
2.4.5.1 Signal transduction-related oncogenes – membrane-associated G 
proteins 
 
The ras family of proto-oncogenes was evaluated in small series of Barrett’s 
oesophagus-associated dysplastic lesions.  The first of these studies that measured 
expression of the proto-oncogene c-Ha-ras, showed that there was no detectable 
expression of c-Ha-ras mRNA in normal or metaplastic oesophageal mucosa 
(Meltzer et al. 1989).  Further analysis confirmed this finding and demonstrated that 
mutations of the ras family of genes were indeed infrequent in Barrett’s oesophagus-
associated neoplasia (Trautmann et al. 1996). 
 
2.4.5.2 Protein kinase related oncogenes 
 
Relatively few studies assessed proto-oncogene abnormalities in Barrett’s 
oesophagus per se.  Jancowski and co-workers (1992) elegantly described positive 
c-erb-B2 immunostaining in 9 of 15 patients with Barrett’s metaplasia as well as 11 
of 15 additional patients with oesophageal adenocarcinoma.  Less frequent 
immunopositivity for c-src, c-ras, c-jun and c-fox was seen in both metaplastic and 
frankly cancerous epithelium (Jankowski et al. 1992).  In another study, c-erb-B2 
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oncoprotein over expression was observed in 7 (11%) of 66 cases of Barrett’s 
adenocarcinoma, but not in surrounding dysplastic and non-dysplastic epithelium 
(Flejou et al. 1994).  In this latter report c-erb-B2 expression was associated with 
poor survival.  More recently, results of studies of other proto-oncogenes have 
appeared in the literature, including the important positive cell cycle regulator, cyclin 
D1 (Arber et al. 1996); the powerful apoptosis inhibitor, Bcl-2 (Goldblum and Rice 
1995); and the prototypical tyrosine kinase proto-oncogene, c-src (Kumble et al. 
1997).  An important study of cyclin D1, expression demonstrated positive nuclear 
staining in 38% of men and 25% of women with Barrett’s oesophagus (Arber et al. 
1996).  In another study, biopsy specimens from 11 of 12 patients with oesophageal 
adenocarcinoma stained positive for cyclin D1 and a statistically significant risk for 
progression to adenocarcinoma (OR 6.85; 95% CI 1.57 to 29.91, p 0.0106) was 
found in the patients who stained positively for this biomarker (Bani-Hani et al. 2000). 
2.4.5.3 Nuclear oncogenes 
The role of nuclear oncogenes that encode transcriptional regulatory proteins and 
that are involved in protein-protein interaction is exemplified by the myc family.  The 
c-myc protein product is involved in critical cellular functions such as proliferation, 
differentiation, apoptosis, transformation, and transcriptional activation of key genes 
(Luscher and Eisenman 1990).  The c-myc gene is located on chromosome 8q24 
and encodes a nuclear protein thought to regulate the transcription of other genes 
important for cell growth (Dang et al. 1999).  Activation of the c-myc gene may 
contribute to tumour progression by preventing the cells from entering the G0 resting 
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phase.  Studies suggest that c-myc is the target gene of the chromosome 8q high-
level amplifications found in oesophageal adenocarcinomas (Persons et al. 1998; 
van Dekken et al. 1999).  Using in situ hybridization, Abdelatif et al. (1991) found 
enhanced c-myc expression in dysplastic Barrett’s epithelium and adenocarcinomas, 
but not in non-dysplastic Barrett’s mucosa.  In contrast, c-myc could not be detected 
immuno-histochemically in oesophageal adenocarcinomas or BO (Jankowski et al. 
1992).  It is unclear whether amplification or mutation of c-myc plays a significant 
role in the malignant progression to BO, but it appears to have limited prognostic 
value in human oesophageal carcinomas (Miyazaki et al. 1992). 
The transcription factor c-myb has a well-defined role in the differentiation and 
proliferation of immature haemopoietic cells.  Although c-myb expression was initially 
thought to be restricted to the haemopoietic system, elevated levels of c-myb mRNA 
and protein expression have subsequently been detected in human colonic 
carcinomas and pre-malignant adenomatous polyps, suggesting that up-regulated c-
myb expression may lead to hyperproliferation of colonic mucosa and, therefore, 
plays an important role in the early neoplastic progression of colonic carcinogenesis 
(Ramsay et al. 1992). 
 
The role of c-myb mRNA expression in Barrett’s oesophagus has been elucidated by 
Brabender et al. (2001).  This study demonstrated that c-myb expression levels 
increased progressively and significantly in histopathologically worse tissue types, 
with an increase from normal squamous oesophagus mucosa to Barrett's intestinal 
metaplasia, and from Barrett's intestinal metaplasia to adenocarcinoma of the 
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oesophagus (p = 0.002).  Median c-myb expression levels were also significantly 
higher in histologically normal squamous oesophagus tissues from cancer patients 
compared to normal oesophagus tissues from patients without cancer (p < 0.001) 
and a control group without evidence of Barrett's oesophagus or gastro-oesophageal 
reflux disease (p = 0.003).  Very high c-myb mRNA expression levels were found 
only in patients with cancer. 
 
2.4.6 Prostaglandins 
Cyclo-oxygenases are membrane-associated proteins that catalyze the rate-limiting 
step in the prostaglandin (PG) production pathway (Dubois et al. 1998; Forman et al. 
1996).  There are two different isoforms of COX: COX-1 and COX-2.  COX-1 is 
constitutively expressed and is involved, for example, in cytoprotection of gastric 
mucosa.  In contrast, COX-2 is normally absent in most tissues, but is transiently 
induced by pro-inflammatory cytokines and growth factors and is involved in 
inflammation and mutagenesis.  They can promote angiogenesis, inhibit immune 
surveillance, increase cell proliferation, reduce apoptosis and cell adhesion, and bind 
to the nuclear peroxisome proliferation activator receptors that act directly as 
transcription factors on ligand binding (Tsujii et al. 1998; Gupta and Dubois 2001; 
Souza et al. 2001).  However, inhibition of expression can decrease cell growth and 
increase apoptosis in vitro in oesophageal adenocarcinoma cell lines (Guo et al. 
2002).   
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Gastrin has been shown to induce proliferation and COX-2 expression in gastric and 
intestinal cells through the activation of the cholecystokinin 2 (CCK2) receptor 
(Konturek et al. 2003; Abdalla et al. 2004).  Abdalla et al. (2004) found that COX-2 
expression was significantly increased in all Barrett’s oesophagus before the 
development of dysplasia.  Expression was highly variable within Barrett’s dysplasia 
and adenocarcinoma samples independent of differentiation status.  In a longitudinal 
case-control study, the expression levels within patients increased over time, 
regardless of the degree of malignant progression.  Biopsies from non-dysplastic 
Barrett’s esophagus expressed increased gastrin mRNA levels compared with other 
biopsies.  Gastrin significantly induced COX-2, prostaglandin E2, and cell proliferation 
in biopsies and cell lines.  They concluded that COX-2 is up-regulated early in the 
Barrett’s metaplasia sequence and that during carcinogenesis; gastrin is a significant 
determinant of COX-2 activity levels via the CCK2 receptor. 
2.5  Oxidative stress and iron  
Iron overload could enhance the production of reactive oxygen and nitrogen species 
in the oesophageal epithelium, which could lead to the formation of Barrett's 
oesophagus.  Oxidative damage has been proposed to be closely related to reflux 
oesophagitis as a driving force for adenocarcinogenesis (Fitzgerald et al. 1996).  c-
Myc is regulated by iron and represses the natural resistance-associated 
macrophage protein-1 (NRAMP1/SLC11A1) gene, which in turn modulates the 
cytoplasmic iron pool (Bowen et al. 2002).   
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2.5.1 NRAMP1/SLC11A1 (solute carrier family 11 member a1) 
 
The natural resistance-associated macrophage protein (NRAMP1/SLC11A1) family 
consists of Nramp1, Nramp2, and yeast proteins Smf1 and Smf2.  The 
NRAMP/SLC11A family is a novel family of functional related proteins defined by a 
conserved hydrophobic core of ten transmembrane domains (Govoni and Gros 
1998).   NRAMP1/SLC11A1 is an integral membrane protein expressed exclusively 
in cells of the immune system and is recruited to the membrane of a phagosome 
upon phagocytosis (Pinner et al. 1997).  By controlling divalent cation concentrations 
NRAMP1/SLC11A1 may regulate the interphagosomal replication of bacteria.  
Mutations in NRAMP1/SLC11A1 may genetically predispose an individual to 
susceptibility to infectious diseases including leprosy and tuberculosis.  
NRAMP1/SLC11A1 regulates macrophage functions that are of potential importance 
in the induction and/or maintenance of autoimmune diseases such as rheumatoid 
arthritis, type I diabetes and Crohn's disease.  NRAMP2 is a multiple divalent cation 
transporter for Fe2+, Mn2+ and Zn2+ amongst others it is expressed at high levels in 
the intestine; and is major transferrin-independent iron uptake system in mammals 
(Pinner et al. 1997).  The yeast proteins Smf1 and Smf2 may also transport divalent 
cations (Lapham et al. 2004). 
 
By depleting the macrophage cytosol of iron, the NRAMP1/SLC11A1 gene affects 
iron-regulated gene expression and iron-dependent processes such as cell growth 
for which iron is essential.  NRAMP1/SLC11A1 expression is repressed and 
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activated by the proto-oncogene c-myc and miz-1 (c-myc-interacting zinc finger 
protein 1) respectively (Yeung et al. 2004).  These authors recently reported a study 
in which they investigated if c-myc regulates NRAMP1/SLC11A1 expression.  They 
were able to show an inverse correlation with cell growth, and in co-transfection 
experiments c-myc repressed the NRAMP1/SLC11A1 promoter.  The 
NRAMP1/SLC11A1 gene has been linked to various infectious (allele 2) and 
autoimmune (allele 3) diseases, which has been ascribed largely to the effect of the 
functional 5’-[GT] repeat polymorphism in the promoter region of the gene (Searle 
and Blackwell 1998). 
 
2.6 The significance of gene expression analysis in Barrett’s Oesophagus 
 
Recent advances in biotechnology have revolutionised the large-scale analysis of 
gene expression.  In particular, the development of high-throughput quantitative real-
time polymerase chain reaction (PCR) (Heid et al. 1996) and c-DNA micro-array 
technologies has made it possible to analyse the expression of a large panel of 
genes simultaneously.  These techniques, in combination with advances in bio-
informatics, promise more accurate disease classification, earlier detection and 
higher efficiency in the field of cancer diagnosis (Perou et al. 2000). 
 
In order to identify genes or combinations of genes that have the power to 
discriminate between pre-malignant Barrett's oesophagus and Barrett's associated 
adenocarcinoma, Brabender et al. (2004) analysed a panel of 23 genes using 
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quantitative real-time PCR (qRT-PCR) and bio-informatics tools.  The genes chosen 
were either known to be associated with Barrett's carcinogenesis or were filtered 
from a previous cDNA micro array study on Barrett's adenocarcinoma.  A total of 98 
tissues, obtained from 19 patients with Barrett's oesophagus (BO group) and 20 
patients with Barrett's associated oesophageal adenocarcinoma (OAC group), were 
studied.  Analysis of the 23 candidate genes together with an internal control gene 
was effected using all samples, for a total of more than 9 016 single PCR reactions.  
It was found that distinct classes of gene expression patterns exist in the different 
types of tissues.  The most informative genes clustered in six different classes and 
had significantly different expression levels in Barrett's oesophagus tissues 
compared to adenocarcinoma tissues.  Linear discriminant analysis (LDA) 
distinguished four genetically different groups.  The normal squamous oesophagus 
tissues from patients with BO or OAC were not distinguishable from one another, but 
Barrett's oesophagus tissues could be distinguished from adenocarcinoma tissues.  
Using the most informative genes, obtained from a logistic regression analysis, it 
was possible to completely distinguish between benign Barrett's and Barrett's 
adenocarcinomas.  A combination of three very informative genes (BFT, TSPAN and 
TP) was found to be the most powerful combination of discriminating between BO 
and Barrett’s associated adenocarcinoma.  This study provided the first non-array 
parallel mRNA quantitation analysis of a panel of genes in the Barrett's oesophagus 
model of multistage carcinogenesis.  The results suggested that mRNA expression 
quantitation of a panel of genes can discriminate between pre-malignant and 
malignant Barrett's disease.   
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Similarly, Mitas et al. (2005) recently reported on using a quantitative three-tiered 
algorithm and multi-marker real-time reverse transcription-PCR to accurately 
discriminate between Barrett's oesophagus and OAC.  They showed that OAC can 
be distinguished from normal oesophagus (NE) and oesophageal squamous cell 
carcinoma by plotting expression values for EpCam, TFF1, and SBEM in three-
dimensional Euclidean space.  They developed a highly sensitive assay for 
monitoring progression of Barrett's oesophagus to OAC whereby 50 ng of RNA are 
first converted to cDNA using 16 gene-specific primers.  A novel quantitative three-
tiered algorithm using only 3 genes allowed for accurate (overall accuracy = 61/63, 
97%) discrimination of Barrett’s oesophagus versus OAC tissues.  The gene used in 
the first tier of the algorithm is TSPAN: samples not diagnosed as BO or OAC by 
TSPAN in the first tier were then subjected to a second-tier analysis using ECGF1, 
followed by a third-tier analysis using SPARC.  A five-gene marker panel by adding 
TFF1 and SBEM to the first tier increased the overall accuracy of their assay to 98% 
(62/63) and resulted in mean molecular diagnostic scores (± SD) that were 
significantly different between OAC and Barrett’s oesophagus samples (3.19 ± 1.07 
versus –2.74 ± 1.73, respectively).  The data generated by this study suggests that 
relatively few genes can be used to monitor progression of Barrett’s oesophagus to 
oesophageal adenocarcinoma. 
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2.7 Aims of the Study 
 
The overall objective of the present study was to define a panel of clinically useful 
biomarkers for genomic and/or transcriptional profiling in South African patients with 
Barrett's oesophagus.  Although the prevalence of Barrett’s oesophagus in the local 
population is similar to that reported in the literature, there is a distinct difference 
amongst ethnic groups.   
 
The selection of the COX-2, c-myc and c-myb genes for inclusion in the study was 
based on literature reports indicating progressively increased expression at an early 
stage through the metaplasia-dysplasia-adenocarcinoma sequence.  The 
NRAMP1/SLC11A1 gene was studied due to its role in iron dysregulation and 
interaction with c-myb, also involved in iron regulation.  In addition, TP53 was 
included because protein over expression has consistently been reported in Barrett’s 
oesophagus and is considered to be the commonest genetic event in human 
malignancy.  Availability of a genetic assay that includes different risk markers that 
are evaluated within the context of environmental risk factors, may lead to effective 
risk reduction intervention tailored to the needs of the individual.  One could envision 
lengthening endoscopic surveillance intervals for patients at low risk for developing 
adenocarcinoma, and intensifying endoscopic surveillance intervals for patients at 
increased risk of developing adenocarcinoma. 
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The specific aims were: 
1) mRNA expression analysis of the COX2, c-myb and c-myc genes to identify 
differential expression patterns in patients with varying degrees of gastro-
oesophageal disease severity; 
2) Analysis of the GT-repeat polymorphism in the promoter region of the 
NRAMP1/SLC11A1 gene to determine whether c-myc mRNA expression patterns 
are confined to certain genotypes due to possible gene-gene interaction; 
3) Analysis of TP53 by using mutation detection and immuno-histochemistry to 
define the role of this gene in the metaplasia-dysplasia-adenocarcinoma 
sequence in the study population. 
 
It is envisaged that molecular studies performed in the genetically diverse South 
African population will provide a better understanding of the disease mechanisms 
underlying the progression from BM to BAC. 
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CHAPTER 3 
 
PATIENTS AND METHODS 
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 The Ethics Committee of the Tygerberg Academic Hospital and the University of 
Stellenbosch reviewed and approved the study protocol.  The informed consent form 
used for analysis of the role of iron in health and disease, and particularly the iron-
related genes NRAMP1/SLC11A1 and c-myc studied in the context of several other 
genes, is provided in the Addendum.   
 
3.1 Patients 
 
The study population was recruited from outpatients who routinely attended the 
Gastroenterology Clinic at Tygerberg Academic Hospital during a 3-year period 
starting June 2001.  This included Caucasians of European ancestry, individuals of 
mixed ancestry (coloured population of San, Khoi, African Negro, Madagascar, 
Javanese and Western European origin) and black Africans.  Written informed 
consent was obtained from each patient.  Particular attention was given to the ethical 
aspects of genetic testing.  The patients were given the assurance of confidentiality, 
and were informed of the possible benefits that could be derived from participation.  
It was also explained to the study participants that the meaning of genetic alterations 
that may be detected and its association with health or disease may be uncertain, 
and that they may not be informed of the findings.  
 
In total 105 patients were recruited for determination of mRNA expression (COX-2, 
c-myb and c-myc) in oesophageal biopsy specimens.  The study population for the 
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determination of mRNA expression consisted of 26 individuals with Barrett’s 
metaplasia (BM) without dysplasia; 14 with Barrett’s oesophagus and dysplasia 
(BD); 2 patients with Barrett’s adenocarcinoma (BAC); 19 with erosive oesophagitis; 
25 with non-erosive oesophagitis and 19 patients with a normal gastroscopy and no 
gastro-oesophageal reflux (GORD) symptoms used as controls.  Matching 
squamous oesophageal tissue were also collected from all the BM and BD/BAC 
patients (n=42). Analysis of the functional GT-repeat polymorphism in the promoter 
region of the NRAMP1/SLC11A1 gene was performed in 199 patients.  Finally, the 
TP53 gene was studied in 68 Barrett’s patients including 2 with BAC, 12 with BD and 
54 with BM, and protein immunostaining was performed in 36 BM and 19 low-grade 
BD specimens. 
 
Both male and female patients more than 18 years of age were included in the study.  
Relevant demographic data was collected that included age, gender, race, smoking 
history and alcohol consumption, age of onset and duration of reflux disease.  A 
questionnaire (see addendum) was used to denote personal details (including 
lifestyle and dietary factors), family history and clinical characteristics.  All the 
patients, with the exception of the controls, suffered from chronic gastro-
oesophageal reflux disease.  This was defined as the presence of one or more of the 
typical reflux symptoms (i.e. heartburn, acid regurgitation and 
dysphagia/odynophagia) for at least 6 months, experienced on a regular basis (i.e.  
at least 3 times per week).  The prior use of proton pump inhibitors and non-steroidal 
anti-inflammatory drugs were recorded.  Body mass index (BMI = weight in kg/height 
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m2) was calculated for each patient.  The data was computerised for statistical 
comparisons.   
 
3.2 Methods 
 
3.2.1 Endoscopic procedure 
 
Upper endoscopy was performed as described previously (Weston et al. 1999).  
During endoscopy the presence of a hiatus hernia and any mucosal abnormalities in 
the oesophagus were recorded.  Non-erosive reflux disease (NERD) was diagnosed 
when a patient displayed typical reflux symptoms (heartburn, acid regurgitation and 
dysphagia/odynophagia) with a normal endoscopy.  In the case of erosive reflux 
oesophagitis, the severity and extent of mucosal breaks (erosions) were recorded 
and classified according to the Los Angeles System (Lundell et al. 1999).  Barrett’s 
oesophagus (BO) was diagnosed by the typical endoscopic appearance of the 
columnar epithelium having a reddish colour and velvet-like texture compared to 
squamous oesophageal epithelium with a pale, glossy appearance.  The length of 
the Barrett’s epithelium was determined in the absence of erosive oesophagitis as 
this might impair the recognition and extent thereof (Sharma 2004).  The oesophago-
gastric junction (OGJ) was defined as where the tubular oesophagus joined the 
saccular stomach (Haggit 1994),  and for patients with hiatus hernias as the point 
where the proximal margins of the gastric folds met the slight circumferential, band-
like narrowing representing the lower oesophageal sphincter (LOS).   
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 Oesophageal biopsies were obtained utilising direct endoscopic vision and the turn 
and suction method using large, fenestrated, spiked 9-mm open span jumbo biopsy 
forceps (FK-13K-1 Olympus).  Short segment BO was defined as Barrett’s epithelium 
length of < 3 cm above the OGJ.  Four-quadrant biopsies of the Barrett’s epithelium 
were obtained at intervals of ≤ 2 cm from the OGJ to the squamo-columnar junction.  
In addition matching biopsies of normal appearing squamous oesophageal tissue 
were taken from the Barrett’s patients and oesophageal biopsies from all non-
Barrett’s patients.   
  
3.2.2 Histological procedure 
 
The specimens for histology were fixed in 10% buffered formalin, stepped serially 
sectioned and then stained with hematoxylin and eosin (H&E).  Goblet cells within 
metaplastic epithelium were confirmed by staining with alcian blue at pH 2.5 i.e.  
histological evidence of oesophageal intestinal metaplasia (confirmed/histological 
BO, Figure 1) (Sampliner 2002).  The diagnosis of low/intermediate grade dysplasia 
(LGD/IGD) and high grade dysplasia (HGD) was according to previously established 
criteria (Haggit 1994).  The histological diagnosis of dysplasia was reviewed 
seperately and agreed on by 2 experienced gastrointestinal pathologists.   
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Figure 1. 
 
Histological appearance of Barrett’s 
metaplastic epithelium stained with Alcian 
Blue.  Goblet cell indicated by arrow.   
 
 
To determine whether TP53 immunostaining might assist in identifying dysplasias, 
especially low-grade dysplasia, histological specimens of 55 patients (36 BM and 19 
BD) were stained with a rabbit polyclonal antibody (NCL-p53-CM1, Novocastra 
Laboratories) Ltd).  This antibody is specific for human wild type and mutant forms 
under denaturing and non-denaturing conditions.  A semi-quantitative scale was 
used from 0 to 3+ scored as follows: 0, fewer than 1% of cells staining; 1, up to 10% 
of cells staining, primarily in the lower third of the crypts; 2, more than 10% but fewer 
than 50% staining; and 3, more than 50% of cells staining. 
 
3.2.3 DNA and RNA analysis 
 
DNA and RNA were extracted using standard techniques to perform mutation 
screening and expression studies using polymerase chain reaction based (PCR)-
based methods.  Molecular studies performed at a private genetic laboratory, 
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included analysis of the NRAMP1/SLC11A1 (susceptibility gene), COX-2, c-myb and 
c-myc genes and TP53 (prognostic marker). 
 
3.2.3.1 DNA extraction and restriction enzyme analysis 
 
Genomic DNA was isolated from whole blood using a salting-out method (Miller et al. 
1988).  The PCR primers used to amplify a 116-bp fragment of the 
NRAMP1/SLC11A1 promoter were 5′-GGGGTCTTGGAACTCCAGAT-3′ (forward) 
and 5′- TACCCCATGACCACACCC-3′ (reverse) (Kotze et al. 2001).  The positions of 
the primers in relation to the NRAMP1/SLC11A1 promoter sequence are shown 
below (forward primer sequence indicated in blue and reverse primer sequence 
indicated in red). 
 
5701   gactcgcattaggccaacgaggggtcttggaactccagatcaaagagaataagaaagacc 
5761   tgactctgtgtgtgtgtacgtgtgtgtgtacgtgtgtgtgtgtgtgtgtggcagaggg 
5821   gggtgtggtcatggggtattgacatgaatacgcaaggggcaggaagcatctgaaatcagagc 
 
DNA amplification was performed in 25 μl reaction volumes containing ~20 ng of 
genomic DNA, 5 mM each deoxyribonucleoside triphosphates (dNTPs), 15 pmol of 
each PCR primer, Mg2+-containing reaction buffer and 0.375 units of DNA Taq 
polymerase (Roche Diagnostics, Switzerland).  A step-down PCR amplification 
procedure was applied with one cycle initial denaturation for 3 minutes at 95°C; ten 
cycles of denaturation at 95°C for 45 seconds; annealing at 65°C for 30 seconds; 
extension at 72°C for 45 seconds; followed by twenty-five cycles of denaturation at 
95 °C for 45 seconds; annealing at 60°C for 30 seconds; extension at 72°C for 45 
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seconds and final extension at 72°C for 10 minutes.  PCR amplification products 
were visualised in 2% agarose (Seakem) by ethidium bromide staining and 
ultraviolet transillumination to confirm successful DNA amplification.  Alleles of the 
SLC11A1 5’[GT]n promoter polymorphism were distinguished by RsaI (Promega 
Inc., UK) restriction enzyme analysis (0.5 units per reaction) as previously described 
(Graham et al. 2000).  Digested PCR products were electrophoresed at room 
temperature in 5% cross-linked polyacrylamide gels at 300 V for 2 hours.  DNA 
fragments in the respective polyacrylamide gels were visualised by ethidium bromide 
staining and ultraviolet transillumination. 
 
3.2.3.2 RNA extraction and expression analysis 
 
Collection of the samples for RNA extraction was standardised to ensure reliable 
expression data.  The biopsy specimens used in the study were obtained at 
endoscopy or operation and were immediately frozen in liquid nitrogen and stored at 
-70°C.  Total RNA was extracted using the Qiagen RNeasy kit.  Aliquots of 8.5 µl 
were immediately used in a RT-PCR reaction in a total volume of 20 µl (Roche, First 
strand cDNA synthesis kit, Mannheim, Germany).  Three complementary primer sets 
were designed (Table 1) (LightCycler probe design, Roche, Mannheim, Germany) 
from Genbank sequences for application of real-time PCR. 
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Table 1.  Primer sets designed across the exon-intron boundaries of the COX-
2, c-myb, c-myc and β-actin (ACTB) genes.   
Gene Sense Antisense 
COX-2 5’- GCTGACTATGGCTACAAAAG-3’ 5’- GATGCGTGAAGTGCTG-3’ 
c-myb 5’- TTCATAGAGACCAGACTGTG-3’ 5’- ACTCAGCAACAAATCCAGA-3’ 
c-myc 5’- CTGGAAGAAATTCGAGCT-3’ 5’- CCACATACAGTCCTGGAT-3’ 
ACTB 5’- AAGAGCTACGAGCTGC-3’ 5’- CACTGTGTTGGCGTACA-3’ 
 
c-DNA synthesised from RNA extracted from normal and abnormal tissue of patients 
with BM were used to optimise the multi-gene assay for expression analysis of the 
COX-2, c-myb and c-myc genes (van Rensburg et al. 2004).  The diagram below 
illustrates the process from sample collection to obtaining the mRNA expression 
results.   
 
 
 
 
 
 
 
 
ENDOSCOPIC OESOPHAGEAL BIOPSY
(Store in RNAlater) 
RNA EXTRACTION 
c-DNA SYNTHESIS 
AMPLIFICATION 
ANALYSIS 
 
 
The RT-PCR was performed using the Roche LightCycler (software version 3.5) 
(Figure 3).   
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 Figure 3.  The Roche LightCycler used to perform mRNA expression analysis 
for the COX-2, c-myc and c-myb genes. 
 
The reaction mixture consisted of cDNA (1 µl), 10 pmol of each primer, 1 µl 
LightCycler FastStart DNA Master SYBR Green 1 Mix (Roche, Mannheim, 
Germany), 500 ng BSA (Gibco, BRL, Gaithersburg, MD) and 3 mM MgCl2 in a total 
volume of 10 µl.  The FastStart polymerase was activated and cDNA denatured by a 
pre-incubation of 10 min at 95˚C.  The template was amplified for 40 cycles of 
denaturation at 95˚C for 0 s, annealing at 60 ˚C for 8 s and extension at 72˚C for 12 
s.  Standard curves for the housekeeping gene β Actin (ACTB) and target (COX-2, c-
myb, c-myc) genes were generated from series diluted cDNAs and analysed using 
the LightCycler quantification software set on the second derivative maximum.  The 
genes of interest and the reference gene were amplified in separate reactions.  Coff 
files were generated when the quality of the standard curve and PCR efficiency 
(E=10(-1/slope)=~2) was optimum (Figure 4).  Reference controls from the standard 
curve were included in each run.   
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   .           
Figure 4.  The fit coefficients or Coff files are created from a dilution series and 
describes the kinetics during the PCR reaction.  The PCR efficiency can be 
calculated using the slope of the standard curve.  A sample from this dilution 
series is included in every run and acts as an external control. 
 
3.2.4  c-DNA sequencing of the TP53 gene 
 
Due to limited c-DNA quantity a nested PCR method was used to amplify the coding 
region of the TP53 gene in two fragments for mutation analysis.  The primer pairs 
are indicated in Table 2. 
 
Table 2.  Primer sets for nested PCR designed for amplification of two 
fragments spanning the TP53 coding sequence. 
  FORWARD PRIMERS REVERSE PRIMERS 
Outside  5’-GTGCTTTCCACGACGGTGAC-3’ 5’-CAAATGGAAGTCCTGGGTGCTT-3’
Fragment 1 
Inside 
5’-GACTGCCTTCCGGGTCACT-3’ 5’-TCCACACGCAAATTTCCTTCCACT-3’
Fragment 2 
Inside 
5’-GCAGTCACAGCACATGACGG-3’ 5’-TGACGCACACCTATTGCAAGCAAG-3’
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The positions of the primers are shown below in relation to the TP53 coding 
sequence.  The initiation codon (ATG) and termination codon (TGA) are underlined.  
The forward primers are indicated in blue and the reverse primers in red. 
 
181 gggagcgtgctttccacgacggtgacacgcttccctggattggcagccagactgccttcc 
241 gggtcactgccatggaggagccgcagtcagatcctagcgtcgagccccctctgagtcagg 
301 aacattttcagacctatggaaactacttcctgaaaacaacgttctgtcccccttgccgt 
361 ccaagcaatggatgatttgatgctgtccccggacgatattgaacaatggttcactgaag  
421 acccaggtccagatgaagctcccagaatgccagaggctgctccccgcgtggcccctgcac 
481 cagcagctcctacaccggcggcccctgcaccagccccctcctggcccctgtcatcttctg 
541 tcccttcccagcccccctaccagggcagatacggtttccgtctgggcttcttgcattctg 
601 gacagccaagtctgtgacttgcacgtactcccctgccctcaacaagatgttttgccaac 
661 tggccaagacctgccctgtgcagctgtgggttgattccacacccccgcccggcacccgcg 
721 tccgcgccatggccatctacaagcagtcacagcacatgacggaggttgtgaggcgctgcc 
781 cccaccatgagcgctgctcagatagcgatggtctggcccctcctcagcatcttatccgag 
841 tggaaggaaatttgcgtgtggagtatttggatgacagaaacacttttcgacatagtgtgg 
901 tggtgccctatgagccgcctgaggttggctctgactgtaccaccatccactacaactaca 
961 tgtgtaacagttcctgcatgggcggcatgaaccggaggcccatcctcaccatcatcacac 
1021 tggaagactccagtggtaatctactgggacggaacagctttgaggtgcgtgtttgtgcct 
1081 gtcctgggagagaccggcgcacagaggaagagaatctccgcaagaaaggggagcctcacc 
1141 acgagctgcccccagggagcactaagcgagcactgcccaacaacaccagctcctctcccc 
1201 gaccaaagaagaaaccactggatggagaatatttcacccttcagatccgtgggcgtgagc 
1261 gcttcgagatgttccgagagctgaatgaggccttggaactcaaggatgcccaggctggga 
1321 aggagccaggggggagcagggctcactccagccacctgaagtccaaaaagggtcagtcta 
1381 cctcccgccataaaaaactcatgttcaagacagaagggcctgactcagactgacattctc 
1441 cacttcttgttccccactgacagcctcccacccccatctctccctcccctgccattttgg 
1501 gttttgggtctttgaacccttgcttgcaataggtgtgcgtcagaagcacccaggacttcc 
1561 atttgctttgtcccggggctccactgaacaagttggcctgcactggtgttttgttgtggg 
 
 
The FastStart polymerase was activated and cDNA denatured by a pre-incubation of 
10 min at 95˚C.  The template was amplified for 40 cycles of denaturation at 95˚C for 
15s, annealing at 60 ˚C for 45s and extension at 72˚C for 60s, with a final extension 
of 10 minutes.  The PCR products were sequenced bidirectional using an ABI Prism 
3130 Genetic Analyser (Applied Biosystems) according to the manufacturer’s 
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instructions.  Sequence alignment and analyses were performed using the GAP4 
genome assembly program (Bonfield et al. 1995). 
 
3.2.5 Statistical analysis 
 
One-way Analysis of Variance (ANOVA) was used to identify significant differences 
in mRNA expression levels among the histopathological groups for the COX-2, c-
myb, and c-myc genes.  The chi-square test was used to determine dependencies 
between the groups and whether the patient samples showed increased mRNA 
expression or not.  A 5% significance level (p<0.05) was used as guideline for 
determining significant differences.  NRAMP1/SLC11A1 genotype and allele 
frequencies were analysed by STATISTICA 7 for Windows (StatSoft.  Inc.  1984 – 
2005), which offers different methods to determine significant associations in the 
study population.  The Chi-square (ҳ2-) test and/or Fischer-exact test were performed 
to assess significant associations with NRAMP1/SLC11A1 in the study population.   
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CHAPTER 4 
 
RESULTS 
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4.1 Prevalence of Barrett’s oesophagus 
 
The prevalence of Barrett’s oesophagus (Figure 1) was determined in 1606 
consecutive patients with chronic gastro-oesophageal reflux disease that attended 
the Tygerberg Hospital Gastroenterology Clinic over a 6 months’ period.  The overall 
prevalence of Barrett’s oesophagus was 3% (Table 1).  White males had the highest 
prevalence (8%), followed by white females (5%) and males of mixed ancestry (4%).  
Only one percent of the females of mixed ancestry presented with Barrett’s 
oesophagus, while one black male had Barrett’s oesophagus.   
 
Figure 1.  Endoscopic view (left panel) of an adenocarcinoma (arrow) developing in a 
Barrett’s segment).  The right panel depicts the histological confirmation (H & E) of the 
adenocarcinoma.  
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Table 1.   Prevalence of Barrett’s oesophagus in 1606 patients with chronic 
reflux disease assessed over a six months’ period. 
Sex Race Total Barrett’s Prevalence 
Female Mixed Ancestry 900 7 1% 
 Black 55 0 0% 
 Caucasian  215 11 5% 
Male Mixed Ancestry 291 13 4% 
 Black 27 1 0.03% 
 Caucasian 118 10 8% 
Total  1606 41 3% 
 
 
4.2 Demographic, Endoscopic and Histological Data 
 
The demographic data of the patients selected for gene expression analysis is 
summarised in Table 2.  Of note is that in the Barrett’s study population 14/26 
patients with metaplasia only, and 7/16 patients with dysplasia and/or 
adenocarcinoma (Figure 2) had a short segment (< 3cm).  A hiatus hernia was 
present in more than 60% of patients.  The mean reflux duration was significantly 
more in the Barrett’s dysplasia / adenocarcinoma group (28.3 ± 22 years).  There 
was only one patient with severe dysplasia in the short segment Barrett’s group.   
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 Table 2.  Demographic, Endoscopic and Histological Features of the Study 
Population. 
 Controls (n=19) NERD 
(n=25) 
ERD (n=19) BM (n=26) BD/BAC (n=16)
Age (mean ± 
SD, yr) 
41.3± 12.9 41.8 ± 9.8 44.0 ± 8.3 62 ± 16 67 ± 13 
Gender 
     Male 
     Female 
 
6 
13 
 
6 
14 
 
10 
10 
 
17 
9 
 
7 
9 
Race               
    Caucasian 
     Mixed  
     Black 
 
1 
16 
2 
 
5 
20 
0 
 
0 
18 
1 
 
17 
9 
0 
 
10 
6 
0 
Smoking – 
mean pack 
years  
17.1 ± 13.4 
(n=10) 
12.0 ± 9.3 
(n=12) 
6.36 ± 5.1 
(n=13) 
47.1 ± 46.2 
(n = 13) 
31.7 ± 26.4 
(n = 9) 
Mean age (yrs) 
of reflux onset  
 31.3 ± 12.5 37.4 ± 10.1 41.0 ± 22 37 ± 16 
Mean reflux  
duration (yrs) 
 11.2 ± 12.9 6.7 ± 7.0 12.4 ± 9.6 28.3 ± 22 
Barrett’s ≤ 3 cm  
≥ 3 cm 
   14 
12 
7 
9 
Hiatus hernia      
     Yes   
      No 
 
 
0 
 
23 
2 
 
16 
3 
 
20 
6 
 
7 
9 
Histology  
No dysplasia 
LGD 
HGD/AC 
    
26 
 
 
13 
3 
BMI (kg/m2) 27.6 ± 6.3 26.8 ± 5.5 28.9 ± 9.2 21.4 ± 13.0 27.4 ± 9.6 
NERD, non-erosive oesophagitis;  ERD,  erosive oesophagitis;  BM, Barrett’s metaplasia;  
BD, Barrett’s dysplasia;  BAC, Barrett’s adenocarcinoma;  LDG, low grade dysplasia;  
HGD, high grade dysplasia;  AC, adenocarcinoma;  BMI, body mass index. 
 
4.3 COX-2, c-myb and c-myc mRNA expression 
mRNA expression levels were determined for COX-2, c-myb and c-myc in control 
samples and Barrett’s patients (Figure 2).  In the normal, non-erosive (NERD) and 
erosive reflux oesophagitis (ERD) groups 14% (9/63) had marginally increased 
expression of c-myb mRNA, compared with 48% (20/42) in the Barrett’s patients    (p 
= 0.002).  Increased c-myb mRNA expression was also found in the matching 
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squamous cell epithelium (MSE) of 14% (6/42) of the Barrett’s patients studied. 
COX-2 and c-myc mRNA levels were not increased in MSE, NERD and control 
samples, while only a few individuals showed increased levels in the ERD and 
Barrett’s groups.  
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Figure 2.  Percentage of patients with increased mRNA expression (> 1.0) for 
COX-2, c-myc and c-myb in control individuals with a normal gastroscopy 
(n=19), erosive oesophagitis (n=19), non-erosive oesophagitis (n=25) and 
Barrett’s oesophagus (n=42). 
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Eleven patients in the BD/BAC group 69% (11/16) showed increased c-myb mRNA 
expression compared with 35% (9/26) in the BM group (p = 0.03) (Figure 3).  c-Myb 
(1,02 and 2,59) and COX-2 (6,7 and 1,52) but not c-myc (0,24 and 0,42) mRNA 
levels were increased in the adenocarcinoma tissue of the two patients with BAC. A 
similar expression pattern was seen for c-myb in the dysplastic tissue of these 
patients (1,75 and 2,59) , while one also showed COX-2 overexpression (0,58 and 
1,52). In comparison, none of the three genes showed increased mRNA expression 
in the matching normal tissue of the patients diagnosed with BAC.   
 
Categorized Histogram: group x c-myb in Barrett's epithelium over expressed
Chi-square test: p=.03287 Fisher exact, one-tailed p=.03287
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Figure 3.  c-Myb over expression in Barrett’s patients with and without 
dysplasia.   
 
 
c-Myb mRNA over expression occurred equally in patients with short and long 
segment Barrett’s oesophagus.  In the BD group 21 % (3/14 patients) had 
increased c-myc mRNA expression compared to none with BM (p < 0.05) and 
BAC.  No significant associations were observed for COX-2 in any of the study 
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groups.  Mean expression levels for mRNA in the Barrett’s patients and non-
Barrett’s control groups combined (normal, ERD, NERD) are depicted in Table 3.  
The mean c-myb mRNA expression was significantly higher (p < 0.01) in Barrett’s 
patients (1.40 ± 1.43), compared with those without Barrett’s (0.62 ± 0.44). There 
was a significant progressive elevation of c-myb expression through the stages of 
Barrett’s intestinal metaplasia to dysplasia/adenocarcinoma. No significant 
differences in mRNA expression levels were observed between ethnic groups for the 
genes analysed (Figure 4).   
 
Table 3.  Mean mRNA levels of patients with Barrett’s metaplasia with and 
 without dysplasia or adenocarcinoma in the abnormal oesophageal tissue. 
 c-myb mRNA (mean ± SD) Percentiles (25th-75th) 
NB (n=63) 0.62 ± 0.44* 0.31-0.83 
BM (n=26) 1.24 ± 1.62# 0.4-1.25 
BD/BAC (n=16) 1.68 ± 1.03# 0.69-2.29 
Barrettt’s total (n=42) 1.40 ± 1.43* 0.49-1.97 
*Non-Barrett’s vs Barrett’s total group: p < 0.01 
#BM vs BD/BAC: p = 0.04 (this p-value was obtained by using the Mann-Whitney test 
and is considered to be only marginally significant, because the ANOVA p-value was 
found to be 0.34). NB, non-Barrett’s group including 19 controls, 25 non-erosives 
and 19 erosives; BM, Barrett’s metaplasia; BD, Barrett’s dysplasia. 
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Figure 4. Ethnic comparison of mean levels of c-myb mRNA expression. 
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 None of the patients used non-steroidal anti-inflammatory drugs.  In the Barrett’s 
groups only three patients took aspirin as cardiovascular protection on a regular 
basis.  Two of these patients had increased c-myb mRNA expression and one 
increased c-myc mRNA expression.  Of the 39 patients with no such history, 18 had 
increased c-myb mRNA expression, two c-myc mRNA expression and two COX-2 
mRNA expression.  Thirteen of the Barrett’s patients were on maintenance proton 
pump inhibition.  Of these patients, 6 had increased c-myb mRNA expression and 
one increased c-myc mRNA expression.  Twenty-nine patients were not on 
maintenance proton pump inhibition.  Fourteen of these patients had increased c-
myb expression and two each increased c-myc and COX-2 expression. 
 
4.4. Genotyping of the 5’-[GT]n repeat polymorphism in the  
  promoter region of the NRAMP1/SLC11A1 gene  
 
The DNA samples extracted from blood samples of 199 patients were genotyped for 
the NRAMP1/SLC11A1 promoter polymorphism.  Figure 5 shows a representative 
gel electrophoresis pattern following restriction enzyme analysis using Rsa I 
digestion. 
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 57 bp 
48 bp 
Figure 5.  Restriction enzyme analysis using RsaI digestion and 
polyacrylamide gel electrophoresis.  Heterozygotes with both alleles 2 and 3 
show two DNA fragments of 57 bp and 48 bp respectively, homozygotes for 
allele 2 have two upper bands and homozygotes for allele 3 have two lower 
bands (see arrows). 
 
The genotype distribution and allele frequencies of the NRAMP1/SLC11A1 5′[GT]n 
repeat polymorphism in controls and patients subdivided according to histology and 
ethnic background are summarised in Table 4.   
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Table 4.  Genotype distribution and allele frequencies of the NRAMP1/SLC11A1 
5’[GT])n repeat polymorphism in controls and patients subdivided according 
to histology and ethnic background (numbers observed are indicated with 
percentages in brackets). 
POPULATION NRAMP CONTROLS NERD ERD BM BD# 
White (n=47) Genotype 4 6 9 28 12 
 2/2 0(0%) 3(50%) 1(11%) 4(14%) 1(8%) 
 2/3 1(25%) 2(33%) 3(33%) 10(36%) 3(25%) 
 3/3 3(75%) 1(17%) 5(56%) 14(50%) 8(67%) 
 Allele n=8 n=12 n=18 n=56 N=24 
 2 1 8 5 18 5 
 3 7 4 13 38 19 
Mixed (n=150) Genotype 20 64 48 18 5 
 2/2 1(5%) 6(9%) 5(10%) 1(6%) 0(0%) 
 2/3 8(40%) 27(42%) 16(33%) 5(28%) 1(20%) 
 3/3 11(55%) 31(48%) 27(56%) 12(67%) 4(80%) 
 Allele n=40 n=128 n=96 n=36 n=10 
 2 10 39 36 7 1 
 3 30 89 60 29 9 
Black (n=2) Genotype 1 0 1 0 0 
 2/2 0 0 0 0 0 
 2/3 0 0 0 0 0 
 3/3 1 0 1 0 0 
 Allele n=2 n=0 n=2 n=0 n=0 
 2 0 0 0 0 0 
 3 2 0 2 0 0 
Total (n= 199) Genotype 25 70 58 46 17 
 2/2 1(4%) 9(13%) 6(10%) 5(11%) 1(6%) 
 2/3 9(36%) 29(41%) 19(33%) 15(33%) 4(24%) 
 3/3 15(60%) 32(46%) 33(57%) 26(57%) 12(71%) 
 Allele n=50 n=140 n=116 n=92 n=34 
 2 11 47 31 25 6 
 3 39 93 85 67 28 
#Numbers for BD and OAC are combined for statistical comparisons 
 
The 3/3 genotype was most common (108/199, 54%) and the 2/2 the least (22/199, 
11%) in the patient groups studied.  Statistically, there was no significant difference 
in the genotype distribution between the ethnic groups.  Similarly, there was no 
statistical significant difference in the allele frequencies in the different patient groups 
(Barrett’s oesophagus, ERD, NERD and the controls, p=0.40) studied.  Likewise, 
there was no difference in the genotype distribution or allele frequencies in the 
Barrett’s group with or without dysplasia (p=0.57).   
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 4.5 Analysis of NRAMP1/SLC11A1 in relation to mRNA expression 
 
In the Barrett’s patient group, only 3 patients with dysplasia had increased c-myc 
mRNA expression.  None of these patients demonstrated the most common 3/3 
genotype.  One of these patients had a 2/2 and the other two a 2/3 genotype.  The 
genotype distribution of the patients with Barrett’s oesophagus that showed an 
increase in c-myb mRNA expression (Figure 6), was similar to the patients with no 
increase and matched the distribution pattern of the patient group as a whole, with 
the 3/3 genotype being the most common.  Only 5 patients with Barrett’s 
oesophagus had an increased COX-2 expression, 2 each of the 2/3 and 3/3 
genotypes, respectively. 
 
Categorized Histogram: c-myb abnormal overexpressed x NRAMP1 RsaI result
Chi-square test: p=.44932
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Figure 6.  NRAMP1/SLC11A1 allele frequencies of Barrett’s patients with and 
without increased c-myb mRNA expression.   
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4.6 c-DNA sequencing and Immuno-staining of TP53 
 
The possible significance of TP53 in the malignant progression of Barrett's 
oesophagus was studied in South African Barrett’s patients by using both immuno-
histochemistry and mutation detection.   
 
4.6.1 TP53 mutation analysis 
 
Direct sequencing of the coding region of the TP53 gene in 68 patients with Barrett’s 
oesophagus revealed two common polymorphisms and two rare mutations (Figure 
7).  Sporadic mutations, G245R (patient no. 563) and D281Y (patient no. 573), were 
detected in two patients with BAC, both in the adenocarcinoma and dysplastic tissue.  
Mutation D281X was also detected in the normal tissue of the patient.  Notably, 
increased c-myb mRNA expression was detected in both TP53 mutation-positive 
patients with BAC.   
 
 
P36P normal CCG-CCA at nucleotide position 108  
 
*
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P36P heterozygote CCG-CCA at nucleotide position 108 
 
 
 
P36P homozygote CCG-CCA at nucleotide position 108 
 
 
 
R72P normal CGC-CCC at nucleotide position 215 
 
*
*
*
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R72P heterozygote CGC-CCC at nucleotide position 215 
 
 
 
R72P homozygote CGC-CCC at nucleotide position 215 
 
*
*
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G245R normal GGC-CGC at nucleotide position 733 
 
*
 
 
G245R homozygote GGC-CGC at nucleotide position 733 
 
*
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D281Y normal GAC-TAC at nucleotide position 841 
 
 
 
D281Y heterozygote GAC-TAC at nucleotide position 841 
 
*
*
 
Figure 7.  Detection of one silent (P36P) and three missense mutations (R72P, 
D281Y and G245R) by direct sequencing of TP53 c-DNA samples.   
*Base changes;  normal, base change absent; heterozygote, one copy; 
homozygote, two copies. 
 
 
 92
The TP53 mutations identified in the study population is summarised in Table 5. 
Similar to previous studies in other populations, polymorphisms R72P and P36P 
were identified at a relatively high frequency in the Barrett’s patients.  These 
missense (R72P) and silent (P36P) mutations are germline mutations since they 
were also identified in the normal tissue of the patients.  The patient with mutation 
D281Y was homozygous for the codon 36 and 72 polymorphisms, and all 3 base 
changes were also present in the matching normal tissue of this patient.  The allele 
frequencies of the wild-type and mutant alleles for R72P are 46% (50/108) and 54% 
(58/108), respectively, in patients with BM.  The mutated allele was detected at a 
lower frequency in the 12 patients with dysplasia (9/24, 37.5%). 
 
Table 5.  TP53 gene variations detected in Barrett’s epithelial/adenocarcinoma 
tissue for 68 patients analysed 
Mutation Barrett’s 
Metaplasia (n=54) 
Barrett’s 
Dysplasia (n=12) 
Adenocarcinoma (n=2) 
P36P 
Exon 4 
4 heterozygotes 
2 homozygotes 
  
R72P 
Exon 5 
26 heterozygotes 
16 homozygotes 
5 heterozygotes 
2 homozygotes* 
 
G245R 
Exon 7 
  1 homozygote* 
D281Y 
Exon 8 
  1 heterozygote*#  
*Mutations G245R and D281Y were also detected in the matching dysplasia tissue. 
#Two copies each of variants P36P and R72P were detected in the same patient. 
Heterozygote, one copy of the mutation, Homozygote, two copies of the mutation 
P, proline;  R, arginine;  G, glycine;  E, glutamate;  D, aspartate;  Y, tyrosine 
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4.6.2 TP53 Immuno-histochemical staining 
 
Immuno-staining using a rabbit polyclonal antibody was performed in 36 BM and 19 
low-grade BD specimens to determine whether TP53 immunoreactivity could help 
with the identification of low-grade dysplasias.  Although more specimens of patients 
with mild BD stained positive for TP53 compared with BM (64 vs. 84%), staining of 
2+ and 3+ intensity was similar in both groups (58%).  As shown in Table 6, TP53 
immuno-staining does not differentiate accurately between mild dysplasia and BM 
(p=0.05) in the South African study group.  
 
Table 6.  Correlation of histological diagnoses with TP53 immunostaining 
intensity* 
Immunostaining Consensus 
Histological 
Category 
0 1 2 3 Total 
Positive 
Total 
 
Barrett’s 
Metaplasia 
 
 
13 (36%) 
 
2 (6%) 
 
18 (50%) 
 
3 (8%) 
 
23 (64%) 
 
36  
 
Low Grade 
Dysplasia 
 
3 (16%) 5 (26%) 7 (37%) 4 (21%) 16 (84%)  19 
*Data are given in numbers (percentage).  Scoring are as follows: 0, fewer than 1% 
of cells staining; 1, up to 10% of cells staining, primarily in the lower third of the 
crypts; 2, more than 10% but fewer than 50% staining; and 3, more than 50% of cells 
staining. 
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CHAPTER 5 
 
DISCUSSION AND CONCLUSION 
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5.1 Epidemiology of Barrett’s oesophagus 
 
Autopsy data provided evidence that the majority of cases of Barrett's oesophagus 
are not detected in the general population, and it is estimated that for every known 
case of Barrett's oesophagus, 20 additional cases go unrecognised (Spechler 1999; 
Eckardt et al. 2001).  Barrett's oesophagus predominates in middle-aged white men 
(Spechler et al. 1994).  Environmental factors play an important role in the 
development of Barrett's oesophagus and it is suggested that the increased 
prevalence may be related to the decline of Helicobacter pylori infection (Guanrei  et 
al. 1988; Macdonald et al. 2000).  Since obesity is an important risk factor for 
oesophageal adenocarcinoma, lifestyle factors may affect the incidence of Barrett's 
oesophagus.  A better understanding of interaction between the genetic and lifestyle 
factors that predisposes an individual to the development and progression of 
Barrett's oesophagus will be crucial for the implementation of effective screening and 
prevention programs in future. 
 
The overall prevalence of Barrett’s oesophagus in our clinic was 3% over a 6-month 
period in 1606 patients assessed for chronic reflux disease.  The findings in 
Caucasians and males of mixed ancestry are in keeping with the reported 
prevalence of approximately 6–12% in patients undergoing endoscopy for symptoms 
of chronic GORD (Sarr et al. 1985; Cameron and Lomboy 1992).  Of the 82 black 
patients with chronic reflux disease, Barrett's oesophagus was diagnosed in one 
individual, which support the evidence that this condition is uncommon in blacks 
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(Spechler et al. 1998, 2002).  In a previous South African study of 216 consecutive 
patients diagnosed with Barrett’s oesophagus between 1970 and 1993, only 5% 
were black (Mason et al 1998).  Segal (2001) reviewed data on the epidemiology of 
GORD, Barrett’s oesophagus, OAC and H. pylori infection in sub-Saharan Africa and 
reported similar findings.  Barrett’s oesophagus is rare and OAC uncommon in all 
regions of sub-Saharan Africa studied (South Africa, Ethiopia, Nigeria, Zimbabwe, 
Kenya and Uganda).  Urbanisation, despite an increase in risk factors associated 
with GORD, has not led to an increase in this disease among Africans, as 
anticipated.  It is believed that the critical factor preventing GORD in black Africans is 
H. pylori infection (with an overall prevalence of 61 – 100%), which is usually 
acquired in childhood, is for life and is probably protective for the oesophagus.   
 
Oesophageal cancer is one of the least studied and deadliest cancers worldwide.  
During the past three decades, important changes have occurred in the 
epidemiologic patterns associated with this disease.  Persons with recurring 
symptoms of reflux have an eightfold increase in the risk of oesophageal 
adenocarcinoma (Lagergren et al. 1999).  Despite the dramatic increase in the 
incidence of oesophageal adenocarcinoma over recent years with a reported 
incidence of 0.5% per year in Barrett’s oesophagus patients (Alderson 2002), we did 
not see a similar trend in our local population.  During the past 5 years only two 
patients presented with an adenocarcinoma that developed in a Barrett’s segment, 
while not a single patient known with Barrett’s oesophagus developed this 
complication over a 5-year surveillance period.   
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5.2 Dysplasia 
 
Dysplasia is a histological diagnosis suggesting that one or more clones of epithelial 
cells have acquired genetic alterations rendering them neoplastic and prone to 
malignancy.  Endoscopic surveillance is performed primarily to identify dysplasia, but 
it is an imperfect predictor of malignancy.  The histological abnormalities of low-grade 
dysplasia are not specific for neoplasia, because similar changes can occur in 
normal tissue in response to injury.  Even among experienced pathologists, the 
extent of inter observer agreement for the diagnosis of low-grade dysplasia in 
Barrett's oesophagus may be less than 50 percent (Skacel et al. 2000; Montgomery 
et al. 2001).  It is not clear whether low grade dysplasia has the same pathogenesis 
and natural history as high grade dysplasia, or whether short-segment disease 
progresses to long-segment disease.  Although logic and indirect evidence suggest 
that the risk of cancer should vary with the extent of oesophageal metaplasia, this 
contention has not been proven (Eckardt et al. 2001). 
 
In the South African study cohort low grade dysplasia was as prevalent in the short 
segment (<3cm) as in long segment Barrett’s (7/14 and 6/14 respectively).  Only one 
of the patients studied had high grade dysplasia.   
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5.3 Genetic studies 
 
Molecular-genetic changes underlying the development of Barrett’s oesophageal 
adenocarcinoma remain poorly understood.  Chromosomal changes are frequent 
and include losses, gains or amplifications.  Results of studies performed to match 
specific chromosomal aberrations with particular genes were inconsistent.  Several 
genes appear to have a central role in cancer development, including COX-2, Bcl-2, 
TP53, p16, p27, cyclin D1, retinoblastoma protein, epidermal growth factor (and its 
receptor), erb-b2, and E-cadherin and the cadherin-catenin complex (Wijnhoven et 
al. 2001; Singh et al. 1998; Shirvani et al. 2000; Katada et al. 1997; Arber et al. 
1996; Yacoub et al. 1997; Polkowski et al. 1999; Krishnadath et al. 1997).   
5.3.1 mRNA expression analysis 
Mitas et al. (2005) recently reported on using a quantitative three-tiered algorithm 
and multi-marker real-time reverse transcription-PCR to accurately discriminate 
between Barrett's oesophagus and OAC, and to monitor progression of Barrett's 
oesophagus to OAC.  In their algorithm, a five-gene panel (TSPAN, ECGF1, 
SPARC, TFF1 and SBEM) increased the overall accuracy of discrimination to 98% 
(62/63) and resulted in mean molecular diagnostic scores (± SD) that were 
significantly different between OAC and Barrett’s oesophagus samples (3.19 ± 1.07 
versus -2.74 ± 1.73, respectively).  Their results suggested that relatively few genes 
can be used to monitor progression of Barrett’s oesophagus to oesophageal 
adenocarcinoma.   
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Once OAC has developed the survival rate is extremely poor.  Therefore, one of the 
main objectives of the present study was to measure c-myb, c-myc and COX-2 
mRNA expression levels to determine whether one or more of these genes have the 
power to improve discrimination between Barrett’s metaplasia without dysplasia and 
Barrett’s associated dysplasia and/or adenocarcinoma in South African patients.  
The genes for mRNA expression were selected on the basis of the previously-
reported increasing levels of expression as relatively early events through the 
metaplasia-dysplasia-adenocarcinoma sequence.   
 
Our study population included patients and controls from different ethnic groups in 
South Africa.  Although the numbers in each subgroup were relatively small, it was 
clear that ethnic differences did not affect the results.  Increased c-myb mRNA 
expression was demonstrated in 69% of patients with Barrett’s associated dysplasia 
or adenocarcinoma compared with 35% in the Barrett’s metaplasia group.  These 
values were significantly higher compared with the control groups, showing 
increased c-myb mRNA expression in only 14% of cases.  These findings are in 
keeping with those reported by Brabender et al. (2001) who used a multi-gene panel 
to distinguish between benign Barrett's and BAC.  Their results have shown that 
up-regulation of c-myb mRNA is an early event in the development of Barrett’s 
oesophagus and associated adenocarcinoma.  High c-myb mRNA expression levels 
therefore seem to be a useful biomarker for the prediction and detection of Barrett’s 
oesophagus.  Once the environmental triggers responsible for cancer development 
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in patients with increased c-myb mRNA expression are known, this marker could 
also serve as a molecular target for implementation of preventative measures. 
 
COX-2 expression has been reported to play an important role in the metaplasia-
dysplasia-carcinoma sequence in Barrett's oesophagus.  This leads to a higher 
proliferation potential, a risk which may be thwarted by non-steroidal anti-
inflammatory drugs administration, inhibits apoptosis and promote tumour 
angiogenesis (Wilson et al. 1998; Amano et al. 2004; Wen et al. 2002).  Expression 
of COX-2 protein has been reported in both dysplastic and non-dysplastic Barrett's 
epithelium (Michael et al. 2003).  In a recent article by Amano et al. (2004), COX-2 
expression was reported in 71% of Barrett's epithelium biopsy samples.  
Surprisingly, in our study only two patients with Barrett’s oesophagus had increased 
expression of COX-2 mRNA levels.  There was no prior non-steroidal anti-
inflammatory drug-intake in our patients and none of the three patients on aspirin 
prophylaxis had increased COX-2 expression. 
 
The importance of c-myc in cellular proliferation and its role in sensitising cells to 
apoptotic triggers is well established.  Tselepsis et al (2003) demonstrated up-
regulation of c-myc mRNA in 33% of Barrett’s metaplasia compared with 84% in 
adenocarcinoma samples.  Comparatively, only 21% (3/14) of our study population 
with Barrett’s associated dysplasia had increased c-myc mRNA expression, but none 
with Barrett’s metaplasia and Barrett’s associated adenocarcinoma.  Failure to show 
similar increases in c-myc mRNA expression through the metaplasia-dysplasia-
 101
adenocarcinoma sequence might relate to the low overall incidence of Barrett’s 
dysplasia and OAC in the local population.  This finding highlights the potential 
significance of external influences on c-myc expression, including acidified bile acid 
and cellular iron status (Goldstein and Yang 1998; Chen et al. 1999). 
 
5.3.2 5’-[GT]n repeat polymorphism in the promoter region of the 
NRAMP1/SLC11A1 gene 
 
In a complementary study the 5’-[GT]n repeat polymorphism in the promoter region 
of the NRAMP1/SLC11A1 gene was analysed to determine whether increased c-myc 
mRNA expression patterns in the realm of gastro-oesophageal reflux disease are 
confined to certain genotypes due to possible gene-gene interaction.  In our 
population group a similar pattern of c-myc mRNA expression in the metaplasia-
dysplasia-adenocarcinoma sequence in Barrett’s oesophagus could not be 
demonstrated as was previously reported by Tselepsis et al. (2003).   
 
The NRAMP1/SLC11A1 gene is involved in the release of iron acquired by 
phagocytic iron uptake.  The basis for the reported inhibition of NRAMP1/SLC11A1 
gene expression by c-myc has still to be clarified (Bowen et al. 2002).  
NRAMP1/SLC11A1 can be induced by pro-inflammatory cytokines, iron and redox 
stress caused by chronic inflammation and as such may have a protective effect.  c-
Myc positively and negatively regulates genes that increase and decrease, 
respectively, the labile iron pool (Wu et al. 1999).  The rationale for c-myc increasing 
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the iron content within the cytosol, is to provide iron for enzymes such as 
ribonucleotide reductase.  It has been shown that iron chelation leads to growth 
arrest.  NRAMP1/SLC11A1-mediated divalent cation flux may deplete the levels 
within the cytosol.   
 
In the patient group as a whole we were unable to demonstrate any statistically 
significant differences in the NRAMP1/SLC11A1 genotype distribution and allele 
frequencies amongst the controls, the patients with NERD and ERD, and the 
patients with Barrett’s with and without dysplasia.  The 3/3 genotype was the most 
common in all study groups, which was in accordance to NRAMP1/SLC11A1 
genotyping in various other population groups, including the genetically distinct 
population groups of South Africa (Kotze et al. 2001. 
 
This study failed to show any significant differences in allele frequencies and 
genotype distribution of the 5΄-(GT)n NRAMP1/SLC11A1 polymorphism in patients 
with Barrett’s oesophagus with and without dysplasia.  However, of the three 
Barrett’s dysplasia patients with increased c-myc mRNA expression none had the 
common 3/3 genotype.  The number of patients with allele 2 is very small, but this 
finding raises the possibility that the presence of allele 2 of NRAMP1/SLC11A1 
increases the risk of high c-myc expression previously implicated in BD and cancer 
development.  It seems possible that unique gene-gene interaction patterns may 
explain differences in mRNA expression profiles and BAC incidences reported in 
populations with diverse genetic backgrounds. 
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 5.3.3 TP53 analysis 
TP53 appears to have both a function as an oncoprotein, perhaps by complexing in 
its mutant form with wild type TP53, and as tumour suppressor gene in its normal 
state (Lane and Benchimol 1990).  Similar to the study performed by Schneider et al. 
(1996), none of the tissue samples from South African patients with Barrett's 
esophagus alone and no dysplasia/adenocarcinoma had any sporadic TP53 
mutations.  These authors performed mutation detection in 50 patients with Barrett's 
adenocarcinoma, of which 23 (46%) had TP53 mutations in Barrett's epithelium, 
tumors, or both.  Twenty of these patients had TP53 mutations in the tumor only (n = 
16) or in both tumor and Barrett's epithelium (n = 4), suggesting that the mutation 
plays a direct role in carcinogenesis.  In three patients with cancer, mutations 
occurred only in Barrett's epithelium, suggesting that such mutations may also be a 
marker for genomic instability.  Mutations were predominantly found in exons 5, 7, 
and 8, the hotspot region of the TP53 gene.  The missense mutations identified in 
the South African patients with BAC were also located in these gene regions.   
In the present study, both patients with BAC had mutations in the TP53 gene, and 
none of the patients with BM or BD alone.  To our knowledge, mutations D281Y and 
G245R were detected for the first time in patients with BAC, while mutation G245R 
has previously been identified in colorectal tumours (Hao et al. 2002).  More than 
half the patients with BM and BD tested positive for the relatively common R72P 
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germline polymorphism.  Two copies of the mutated allele were also detected in the 
patient with the D281Y mutation.   
 
A recent study in Chinese patients with hepatocellular carcinoma has demonstrated 
the potential significance of the R72P polymorphism in the TP53 gene as important 
risk factors for cancer development (Zhu et al. 2005).  The presence of two copies of 
the mutant form (proline) of this genetic variant is associated with the highest risk of 
cancer development and seems to be a useful prognostic marker in patients with 
breast cancer.  In the study performed by Tommiska et al. (2005) in 939 Finnish 
familial and 888 unselected breast cancer patients, as well as 736 healthy population 
controls, the genotype distribution was similar in all groups studied, suggesting no 
association with breast cancer risk.  However, unselected breast cancer patients with 
the 72P homozygous genotype presented significantly more often with lobular 
carcinoma, whereas R72 allele carriers had a significantly higher frequency of ductal 
carcinomas (P = 0.004).  Survival analysis showed that unselected breast cancer 
patients with 72P homozygous genotype had significantly poorer survival than 
patients with other genotypes (P = 0.003).  This effect on survival was independent 
of TP53 expression in the tumors and multivariate analysis showed that 72P 
homozygous genotype was overall an independent prognostic factor.  This finding of 
codon 72 genotype as an independent prognostic marker for breast cancer warrants 
further studies in patients with other cancer types such as BAC. 
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Regarding TP53 immuno-histochemistry analysis, there was a positive correlation 
between epithelial TP53 immunoreactivity and increasing degrees from epithelial 
metaplasia to dysplasia.  This finding confirms those of previous studies examining 
TP53 immunostaining in the metaplasia-dysplasia-adenocarcinoma sequence of 
Barrett esophagus (Coggi et al. 1997; Glickman et al 2001; Weston et al. 2001).  It is 
of interest that the correlation between TP53 protein accumulation detected by 
immuno-histochemical analysis and genetic mutations of the TP53 gene is poor, as 
determined in the present and previous studies (Coggi et al. 1997).  In a recent study 
by Robert et al. (2005) that represents the largest examination of the immunostaining 
of TP53 in relation to dysplasia by a multi-institutional panel of gastrointestinal 
pathologists, they were unable to define a practical use of immuno-histochemical 
staining for TP53 in the most difficult areas of diagnosis, i.e., negative, indefinite, and 
low-grade dysplasia.  The present study supported the potential, but undefined role 
of previous studies of immunostaining for TP53 in the histological assessment of 
dysplasia in biopsy specimens of Barrett’s oesophagus.   
 
Mutations of TP53 are clearly involved in the pathogenesis of Barrett's cancer for a 
subset of patients (~50%).  The fact that mutations could be detected in both the 
dysplastic and adenocarcinoma biopsies of the two South African BAC patients 
studied supports the hypothesis that TP53 mutations may be a useful marker for 
patients at increased risk for development of invasive cancer.  Absence of TP53 
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mutations in the BM and BD (without BAC) patients, suggest that mutations occur as 
relative late events in the metaplasia-dysplasia-adenocarcinoma sequence. 
 
5.4 Management options 
 
Early diagnosis of patients who are progressing toward adenocarcinoma at a curable 
asymptomatic phase has become an important clinical goal.  Only about 5% of 
patients with Barrett’s oesophagus are diagnosed and 0.5-1% of patients with this 
condition per year will actually develop adenocarcinoma (Murray et al. 2003).  Even 
though the overall incidence of BAC is low compared with most other cancers, the 
incidence is increasing rapidly in the Western world and the 5-year survival rate is 
less than 20%. 
 
Despite the fact that endoscopic screening and surveillance for Barrett’s oesophagus 
is the current standard of practice, there is no conclusive evidence that the death 
rate from oesophageal cancer is decreased.  Recommendations for screening and 
surveillance are based on conjecture and questionable models.  Furthermore, it has 
not been proven that any of the treatment options, including aggressive acid 
suppression, anti-reflux surgery, chemoprevention and ablation therapy, affect the 
risk of BAC in chronic GORD.   
 
Currently dysplasia is considered the best predictor of malignancy.  However, it 
represents an imperfect biomarker due to sampling error and interpretation 
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differences among pathologists.  Data on the safety and efficacy of intensive 
endoscopic surveillance of patients with high-grade dysplasia is also limited 
(Enzinger and Mayer 2003).  It is therefore envisaged that targeted genetic testing in 
combination with conventional methods of screening and surveillance may 
significantly improve management of Barrett’s oesophagus patients. 
 
Reliable identification of low-grade dysplasia remains problematic and accurate 
molecular markers of low-grade dysplasia have not previously been identified.  In 
this study c-myb analysis enhanced the diagnostic assessment of low-grade 
dysplasia in Barrett’s oesophagus as almost 70% of BD patients showed mRNA over 
expression.  The role of this gene in risk assessment may be comparable to that of 
many functional polymorphisms that occur in the general population, but at an 
increased frequency in affected patients.  Polymorphic variants occurring in more 
than 1% of the general population may have a relatively large effect on population 
risk but small effect on individual risk, depending on the effect on protein function, if 
any.   
 
Although COX-2 and c-myc over-expression are known to occur early and 
progressively increasingly in the metaplasia-dysplasia-carcinoma sequence, the low 
rate of mRNA over-expression limits the use of these genes as biomarkers for risk 
stratification in the South African population.  Differences in genetic background and 
environmental exposure may underlie these discrepancies between different 
population groups studied.  The expression profiles of cancer-related genes may 
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also be influenced by functional polymorphisms such as NRAMP1/SLC11A1 
analysed in this context.   
 
The detection of pre-neoplastic changes relies almost solely on the careful 
histological evaluation of oesophageal biopsy specimens.  However experts in the 
field agree that the diagnosis of low-grade dysplasia in particular is a subjective 
assessment, with considerable variation even among trained observers.  
Consequently, significant effort has been made to elucidate more objective 
biomarkers in the dysplasia-adenocarcinoma sequence so as to identify patients at 
increased risk for developing cancer.  Attention has been given almost exclusively to 
changes in nuclear programming, especially TP53 mutations or loss of 
heterozygosity, p16 mutations, DNA ploidy, and G1/S DNA content in higher grade 
lesions.  Despite promising results, reliable identification of low-grade dysplasia 
remains problematic.   
 
Identification of high-grade dysplasia, intramucosal and invasive carcinoma is not the 
area of interpretive difficulty in the histological diagnoses of Barrett’s oesophagus.  A 
study by Montgomery et al (2001) showed that consensus histological diagnoses of 
high-grade dysplasia, intra-mucosal carcinoma, or invasive carcinoma correlated 
with high intensity TP53 staining in mucosa.  However, immuno-staining for TP53 in 
the histological assessment of dysplasia in Barrett’s oesophagus, is still undefined.   
Similarly, Robert et al (2005) reported recently on strong positive correlation of TP53 
immuno-reactivity with increasing degrees of epithelial dysplasia and carcinoma.  In 
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this study by using a collapsed dysplasia scale of 4 categories, only 4 of 19 cases 
(21%) of dysplasia stained positively at the +3 level.   
 
The progression of metaplastic epithelium through dysplasia to adenocarcinoma is 
attributable to changes in nuclear regulation.  However, histological identification of 
dysplasia involves assessment of cytoplasmic and nuclear alterations, such as 
epithelial polarity and nuclear/cytoplasmic ratio.  The possibility that markers of 
cellular polarity such as Rab11a might assist in identifying dysplasia, especially low-
grade dysplasia, has been explored only recently (Robert et al 2005).  Although the 
identification of molecular markers of altered cellular polarity is an attractive 
alternative to nuclear markers of low-grade dysplasia the authors were unable to 
distinguish the varying degrees of dysplasia by Rab 11a immuno-histochemical 
analysis.  Therefore it remains an attractive alternative to use c-myb mRNA over 
expression as adjunct to the histological diagnosis in order to define low grade 
dysplasia more accurately in the metaplasia-dysplasia-adenocarcinoma sequence of 
Barrett’s oesophagus.  This practice can simplify the differentiation of low-grade 
dysplasia from inflammatory atypia as well as modify the endoscopic surveillance 
programs of these individuals. 
 
Based on the insight gained through this study, it is proposed that the screening of 
an epidemiological high-risk patient should be combined with genetic testing to more 
accurately identify individuals for intensified surveillance.  Different genetic risk 
factors triggered by environmental factors may contribute to the same disease 
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process.  Therefore the identification of the both genetic and environmental risk 
factors may individualise management in future.  c-Myb mRNA expression was 
confirmed to be a valuable biomarker, as it was increasingly over expressed in the 
metaplasia-dysplasia-carcinoma sequence.  The fact that almost 70% of BO patients 
with low-grade dysplasia showed c-myb over expression, allows for the identification 
of a subset of BO necessitating intensified surveillance and timeous intervention.  
Therefore, the patients with high c-myb mRNA expression included in this study will 
be followed up within the setting of an endoscopic surveillance program.  An 
improved understanding of the molecular biology of Barrett’s oesophagus would 
allow improved diagnosis, prognosis and therapy.   
 
A proposed model for future screening and surveillance of Barrett’s oesophagus in 
the local patient population is depicted in the flow diagram below.  A subset of 
patients with high c-myb mRNA expression could also be subjected to TP53 
mutation detection for improved risk stratification and prognostication. 
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In recent years it became evident that biologic markers of propensity to progress at 
discrete stages of carcinogenesis could help in selecting therapeutic modalities.  It is 
envisaged that genetic studies will in future form an important part of treatment 
choice, similar to assessment of HER2/neu now routinely used to pre-determine 
response to Herceptin treatment in breast cancer (Montemurro et al. 2005).   
 
In conclusion, this study contributed to a much greater understanding of the 
molecular alterations accompanying the metaplasia-dysplasia-adenocarcinoma 
sequence in Barrett’s oesophagus in our study population.  c-Myb mRNA over 
expression has shown to be an important biomarker in this context and can serve as 
an adjunct to the standard practice of regular endoscopic surveillance for patients 
with Barrett’s metaplasia, as it increases progressively through the metaplasia-
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dysplasia-adenocarcinoma sequence.  Data to support the efficacy of endoscopic 
surveillance is lacking worldwide and even more so in the South African context.  A 
combined approach may contribute to more targeted screening, aimed at high-risk 
sub-groups, thereby improving the effectiveness of this practice.  It may also prove to 
be useful in differentiating between an adenocarcinoma arising from the OGJ and a 
true Barrett’s-associated adenocarcinoma.  Given the considerable inter-observer 
variation in histopathology, the finding of increased c-myb mRNA in Barrett’s tissue 
may enhance the efficacy of dysplasia as a biomarker with increased risk of 
progression to adenocarcinoma and lead to more intensified surveillance strategies.  
The highly significant over expression of COX-2 and c-myc mRNA in the metaplasia-
dysplasia-adenocarcinoma sequence as reported in the literature, could not be 
reproduced in the local population.  However, when over expressed this may 
contribute to more effective management strategies.  Similarly, detection of TP53 
mutations is indicative of a poor prognosis and DNA sequencing may be useful to 
identify Barrett’s patients with low-grade dysplasia who are at high risk of 
progression to carcinoma.   
 
It is well known that different genetic backgrounds, gene-gene and gene-
environment interaction may explain different disease patterns in diverse 
populations.  With the established role of iron in the pathogenesis of oesophageal 
adenocarcinoma, patients with a 2/2 and 2/3 genotype of the iron-transporter gene 
NRAMP1/SLC11A1 [5΄-(GT)n repeat polymorphism in the promoter region] combined 
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with over expression of c-myc mRNA may be at increased risk of oesophageal 
adenocarcinoma due to gene-gene interaction.   
 
5.6 Future Prospects 
 
The current practice of endoscopic screening and surveillance of patients with 
Barrett’s oesophagus has clear limitations.  In the future, it is likely that patients who 
have Barrett’s oesophagus will be stratified further according to their risk for 
progression to invasive carcinoma, allowing for the development of more rational 
surveillance programmes.  Models incorporating objective scores of epidemiologic 
risk factors (i.e. age, sex, and body-mass index), reflux symptoms and endoscopic 
and histological findings, would likely include panels of biomarkers for further 
stratification of patients in low, intermediate, or high risk.   
 
No biomarker has yet emerged that is superior to the histological identification of 
dysplasia and it remains to be seen whether other novel approaches, such as high-
throughput hypermethylation analyses or transcriptional profiling using microarray 
technology can prospectively identify molecularly distinct, but histologically 
indistinguishable high-risk groups of BM patients.  The real-time PCR technology 
applied in this study, displaying high inter- and intra-assay reproducibility, is 
considered the ideal method for mRNA expression analysis of highly selected 
clinically useful biomarkers, as it provides statistically confident results.  
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In the South African context, it was confirmed by real-time PCR that c-myb 
mRNA expression in Barrett’s mucosa may be a valuable adjuvant to the 
screening and surveillance of these patients.  c-Myb can be considered a 
clinically useful biomarker for the diagnosis of malignancy in patients with 
Barrett’s oesophagus (Brabender et al. 2001), as upregulation is not a simply a 
function of generalised inflammation but a specific effect leading to 
hyperproliferation (Ramsay et al. 1992).  Additionally, TP53 mutation detection 
may help to identify a subset of Barrett’s patients will progress to cancer 
development.  c-Myb mRNA expression needs to be studied prospectively in 
Barrett’s oesophagus patients to determine the impact of genetic testing on 
clinical outcome.  In future analysis of TP53 mutation status should be combined 
with c-myb mRNA expression to evaluate the predictive value in terms of 
progression.   Ultimately, the use of molecular-genetic tests that can objectively 
identify patients with Barrett’s oesophagus at increased risk of carcinoma may 
lead to improved survival rates. 
 
Genetic testing could possibly be combined with improved sampling techniques 
during endoscopic surveillance programmes, such as the use of brush cytology.  
Although not freely advocated, the latter has the potential to sample tissues more 
widely than endoscopic biopsy and may prove to be more cost-effective.   
 
Finally, biomarker discovery programs are increasingly inextricably linked to the 
search for novel targeted treatments and chemoprevention in Barrett’s patients.  It 
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seems unlikely that future applications of genetic testing would replace existing 
clinical management protocols relying on subjective histological evaluation of 
mucosal biopsy.  However, application of clinically useful makers such as c-myb 
could serve as an important adjunct to identify patients with low-grade dysplasia for 
intensified surveillance intervals. 
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Town: 
a) van Rensburg C, Daniels C, De Villiers JNP, et al. Significance of COX-2, c-
myb and c-myc mRNA expression in the Barrett’s metaplasia (BM)-dysplasia-
carcinoma sequence.  SAMJ 2004 Aug;94(8)680. 
 
b) van Rensburg CJ, de Villiers JNP and Kotze MJ.  Development of a multi-
gene real-time (RT-) PCR assay to study and monitor disease progression in 
the Barrett’s metaplasia (BM)-dysplasia carcinoma sequence.  SAMJ 2004 
Aug;94(8)675.                             
 
2) Digestive Disease Week® and the 106th Annual Meeting of the American 
Gastroenterology Association, 14 – 19 May 2005, Chicago, IL: 
van Rensburg C, Daniels C, De Villiers JNP, et al. Significance of COX-2, c-myb 
and c-myc mRNA expression in the Barrett’s metaplasia (BM)-dysplasia-
carcinoma sequence.  Gastroenterol., 2005;128(Suppl.2): A240 
 
3) World Congress of Gastroenterology, 10 – 14 September 2005, Montreal, 
Canada: 
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population.   
  
4)  13th United European Gastroenterology Week, 15 – 19 October  
2005, Copenhagen, Denmark: 
a] Identification of clinically-informative biomarkers for risk stratification within 
the spectrum of gastro-oesophageal reflux disease in the South African 
population.  Gut 2005;54(Suppl VII):A43 
 
b]  Analysis of the GT-repeat polymorphism in the promoter region of the 
NRAMP1/SLC11A1 gene to determine whether c-myc mRNA expression 
in the realm of gastro-oesophageal reflux disease is confined to certain 
genotypes due to gene-gene interaction.  Gut 2005;54(Suppl VII):A97 
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...........................................................  .......................................... 
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verteenwoordiger    
 144
SUBJECT INFORMATION AND CONSENT FORM 
 
TITLE OF PROJECT: 
Molecular investigation into the role of iron in health and disease 
 
DECLARATION BY PARTICIPANT 
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I understand that, this being research, the meaning of genetic alterations that may be 
detected and its association with health or disease may be uncertain and I will not be 
informed of such findings.  However, if the alteration has been reported or is generally 
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